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Torque teno virus (TTV) was discovered in 1997 in the serum of a Japanese patient
with post-transfusion hepatitis of unknown etiology. TTV is a non-enveloped small virus
containing a circular single-stranded negative-sense DNA genome. TTV resembles in
genome organization the animal pathogen, chicken anemia virus (CAV), of the
Circoviridae family. Thus, TTV represents the first circovirus-like virus found in humans.
Within a few years after its discovery, TTV was noted to have several genotypes. To date,
these viruses are classified into a new floating genus, Anellovirus. TTV was soon shown to
be globally highly prevalent among healthy individuals; up to 94% of subjects are viremic.
Persistent infections and co-infections with several genotypes occur frequently. However,
the pathogenicity of TTV is at present unclear.
To  determine  the  prevalence  of  TTV  in  the  Finnish  population,  we  set  up  PCR
methods and examined the sera of nonsymptomatic subjects for the presence of TTV DNA
and for genotype-6 DNA. We showed that TTV is also very common in Finland: TTV
DNA was detected in 85% of the subjects, and genotype-6 DNA in 4%.
We studied the prevalence of TTV DNA and genotype-6 DNA in human tissues.
TTV DNA was detected in peripheral blood mononuclear cells (PBMC), adenoids, tonsils,
synovia, skin, bile and liver. Genotype 6 TTV-DNA was detected in the latter three, with
no tissue-type or symptom specificity.
The cell biology events during TTV infections are at present unknown. Replicating
TTV DNA has been detected in liver, in PBMC, and in bone marrow; and alternative
splicing has been shown to generate three mRNAs. In order to characterize TTV cell
biology in more detail, we cloned and sequenced the full-length genome of TTV genotype
6. We showed that in clone-transfected human kidney-derived cells TTV produces, by
alternative splicing and by alternative translation initiation, altogether six proteins with
distinct subcellular localizations. The mRNA transcription was detected in the seven cell
lines, and TTV DNA replication in several of them, including cell lines of erythroid and of
hepatic origin. We demonstrated that the replication can be blocked by the drug
aphidicolin, indicating that TTV utilizes for replication the cellular DNA polymerases.
Diagnoses of TTV infections have been based almost solely on PCR. However,
serological tests, measuring antibody responses, would give more information on TTV
infections. In addition, the mechanism for the sustained occurence of the virus in the
circulation is at the moment unknown. To investigate the immunology behind the TTV
infections in more detail, we expressed the six TTV proteins in bacteria and in insect cells
for use as antigens in immunoblotting. We detected in human sera IgM and IgG antibodies
to  occur  simultaneously  with  TTV  DNA,  appearance  of  TTV  DNA  regardless  of  pre-
existing antibodies, and disappearance of TTV DNA after the appearance of antibodies.
The genotype-6 nucleotide sequence remained stable for years within the infected
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individuals, suggesting that some mechanism other than mutations is used by TTV to evade
our immune system and to establish chronic infections in healthy individuals.
In this thesis work we have set up a wide array of methods (e.g. molecular biology
and serology), with which we have determined TTV prevalence in Finland, studied TTV-
related cell biological events (i.e. transcription, replication, and translation), and expressed
TTV proteins for immunological studies. The methods and results presented will be
valuable in TTV research and diagnosis, and can be used to reveal the clinical significance
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REVIEW OF THE LITERATURE
1 INTRODUCTION
Viruses have been infecting cells since the origin of organisms, maybe even since the first
cells. Viruses infecting humans today have either co-evolved with us for thousands of
years, or have entered human populations at various time points. Viruses and viral diseases
have had major impacts on humans throughout history. Nevertheless, it was only until the
19th century that viruses were actually found and described. The first virus to be discovered
was tobacco mosaic virus of a plant. The initial finding, showing that the disease was
caused by something smaller than bacteria or fungi, came in 1892 from a Russian scientist
Dimitrii Ivanovsky. Six years later Martinus Beijerinck from Holland confirmed that this
agent must be smaller and different from any bacteria known: the agent passed through
filters, and multiplied only in a live host. Beijerinck named this filtrate contagium vivum
fluidum (“soluble living germ”), and the agents were named “ultrafilterable viruses” (virus
= “poison” in Latin) (Flint et al., 2004).
2 PROPERTIES OF VIRUSES
Since the discovery of the tobacco mosaic virus, it has become evident that viruses are well
suited for their task: to reproduce themselves. Characteristic for viruses is that they do not
reproduce by division, i.e. viruses do not “grow”; instead, they replicate within cells.
Viruses  are  very  small,  they  contain  nucleic  acid  (RNA  or  DNA)  that  is  protected  by  a
capsid of protein(s). Some viruses have also a lipid bilayer surrounding the capsid (i.e.
enveloped viruses), or inside the capsid (e.g. some bacteriphages). Viruses exist in many
forms (spherichal, helical, with spikes etc.) and sizes. All viruses are obligate cellular
parasites, meaning that viruses totally depend on living host cells for reproduction. Viruses
do not encode ribosomes or mitochondria, and thus can not synthesize proteins or produce
energy. Instead, these life sustaining processes are provided by the host cell. Viruses are
passively moved (by air, water, vectors etc.) into contact with their host cells, into which
they invade, i.e. hijack for their own purposes. Even though viruses are considered
“simple” forms of life, they are far beyond that. They may be small in size, but are able to
perform gigantic tasks, and do have major impacts on their hosts.
Viruses on the whole are cabable of infecting all  living organisms: bacteria,  fungi,  plants,
and animals. In humans, viruses can either invade our body, or infect the cells on our
surfaces (i.e. skin or mucosa). Depending on the infecting virus, and other factors (e.g. the
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subject’s physiological state, environmental factors, etc.), the infection can lead to disease
or remain sub-clinical. When the virus encounters its host cell, the viral life cycle begins:
the virus attaches to the cell, enters it, releases nucleic acid into the cell (uncoating),
replicates genomic material, produces viral proteins (for particles, for genomic synthesis,
and for interactions with the environment), assembles (and matures) into virions, and
finally is released from the cell either with or without cell lysis. Different viruses have
various ways to accomplish this life cycle (Flint et al., 2004).
3 DISCOVERY OF HUMAN VIRUSES AND OF TORQUE TENO VIRUS
3.1 Overview of history and methods in discovery of human viruses
Scientists have always tried to find the underlying cause for various diseases, and to date
viruses have been identified as causal agents for several of those. Interestingly, although the
first vaccine against a virus-caused disease (smallpox) was developed already in 1798, it
was until in 1901 that the first human virus (yellow fever virus) was discovered. By
experimentally infecting humans with mosquitoes and with serum, scientists proved that
mosquitoes were transmitting the disease-causing filterable agent, a virus. The discovery of
human viruses was very slow due to dangers and difficulties in handling of the disease-
causing (and often fatal) agents introduced into human volunteers. The next important
human virus to be discovered was the influenza virus in 1933. Scientists infected ferrets
with  human  throat  washings  and  were  able  to  isolate  the  virus.  Later,  mice  and  chicken
embryos were shown to be infectable with influenza virus, eggs being used still today in
influenza research. These findings led to the use of animal models, which still are
invaluable tools in virus research. The new era on virus research began along with the
invention of the electron microscope in the 1930s. This allowed the visualization of viruses
that  had  earlier  not  been  possible  with  light  microscopes.  In  the  1950s  cell  and  tissue
culture methods were developed, leading to isolation of many human viruses, including
adeno, measles and rubella. These systems allowed for detailed study of the virus life cycle,
providing information not possible to obtain with other methods (Flint et al., 2004).
In the 1980s a dramatic improvement in methods came with the invention of the
polymerase  chain  reaction,  PCR,  used  for  the  amplification  of  DNA (or  RNA).  With  this
method it became possible to amplify genomes of unculturable viruses, and to detect very
small amounts of viral nucleic acids. The post-PCR era has had a major impact on
discovery and characterization of viruses. To date, several methods have been developed
that  utilize  some  form  of  amplification  of  viral  sequences.  In  PCR,  the  restriction  for
amplification  of  unknown viruses  is  that  the  sequence  has  to  be  known.  Therefore,  PCR-
based methods for which prior knowledge of the target sequence was not needed were
developed, e.g. use of degenerate primers or random PCR. In addition, several sophisticated
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amplification techniques have been developed. For example, sequence-independent single
primer amplification (SISPA) has been used to detect unknown sequences that exist in low
amounts. In SISPA, the genetic material is first converted to double-stranded DNA
(dsDNA), then adapters are linked to restriction enzyme digested DNA, and primers
specific for the adapter are used for amplification of the target sequence in between the
adapters. In addition, the differential display technique is used for investigation of
differences in messenger-RNA (mRNA) expression; whole genome amplification
techniques are used for amplification of viral genomes etc. The products are usually cloned
and sequenced, or analyzed by microarray techniques, or by restriction enzyme analyses
combined with gel electrophoresis techniques (Ambrose et al., 2006).
One technique also used in TTV research (see below), is representational difference
analysis (RDA), which reveals the differences in nucleic acid composition between
sequential samples (e.g. during and after disease). In this method, restriction enzyme
digested DNAs from two samples are mixed, then melted, and allowed to anneal. Nucleic
acids  in  one  of  the  samples  are,  prior  to  mixing,  linked  to  a  primer.  The  primer  is  used
subsequently in PCR to amplify sequences in which the primers are present, while the
unlinked nucleic acids remain non-amplified. Thus, exponential amplification of nucleic
acids present only in the primer-labeled sample (i.e. primers at both ends of DNA
fragments) takes place (Ambrose et al., 2006; Lisitsyn et al., 1993).
3.2 Emerging viruses
Emerging viruses are generated from existing ones by mutation (e.g. influenza virus), by
exposure of naïve populations to the existing virus (e.g. due to movement of the infected
hosts), and by changing the microbial host-range (e.g. HIV and CPV). New possibilities for
emergence are often provided by human activity: high density populations, water
regulation, drug abuse, sexual behaviour, increased speed and distance in travelling, and
invasion into new environments (e.g. jungle, sea).
The Webster’s Encyclopedic Unabridged Dictionary of the English Language defines the
verb emerge as follows: 1) to rise or come forth from or as if from water or other liquid; 2)
to come forth into view or notice, as from concealment or obscurity; 3) to come up or arise,
as a question or difficulty; 4) to come into existence, develop; 5) to rise, as from an inferior
or unfortunate state or condition. In this regard, the above explained concept of emerging
viruses should be widened to include viruses that emerge (i.e. are found or detected and
thereby come into existence) by human research. During the post-PCR era, several viruses
that have existed with us for millennia, but unnoticed, have “emerged”. Anelloviruses
described  in  this  thesis  are  an  excellent  example;  not  merely  one  virus,  but  a  large  virus
family living with us.
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3.3 Emergence of TTV
Hepatitis, i.e. inflammation of the liver, affects millions of people worldwide. Severity and
outcome of the disease depend on the etiological agent. Most of the hepatitis cases are
caused  by  infection  with  one  of  the  hepatitis  viruses;  hepatitis  A,  B,  C,  D  or  E
(http://www.who.int/csr/disease/hepatitis/en/). However, there are still numerous hepatitis
cases in which the causal agent is not known. In the search for yet unidentified hepatitis
viruses, TT-virus (TTV) was found in 1997 in Japan from a patient with post-transfusion
hepatitis of unknown etiology. The patient was 58 years old, and had received 35 units of
blood for heart surgery. TTV was detected with the RDA in the serum sample taken during
hepatitis. A clone of approximately 500 bp was obtained, which showed no similarities
with  any  sequences  deposited  in  databases.  TTV  DNA  was  detected  in  the  blood
transiently, during a peak of a liver enzyme, alanine aminotransferase (ALT), elevation
(Nishizawa et al., 1997).
3.4 Evidence for the viral nature of TTV
Nishizawa and coworkers showed by PCR that the TTV genome was of DNA. In addition,
as this DNA was not amplified from the tissues of humans (presumably) free of TTV
infection, it was concluded that it did not originate from human genome. Furthermore,
since it fractionated in sucrose gradient at 1.26 g/cm3, and was resistant to DNaseI, it was
concluded to be encapsidated, and thereby a putative virus. This newly found virus was
named TT-virus according to the initials of the patient (Nishizawa et al., 1997). Later, TTV
was named as Torgue teno virus (latin “torques”, necklace; “tenuis”, thin) (Biagini et al.,
2004). Further studies showed that serum-derived TTV is sensitive to Mung Bean
Nuclease, but resistant to RNaseA and restriction enzymes. Thus TTV was concluded to be
a DNA virus that had a single stranded genome (ssDNA) (Mushahwar et al., 1999;
Okamoto et al., 1998b). Detergent treatment destroys the viral envelope altering the density
of the virus. Since the density of the Tween-80 treated TTV remained unchanged in sucrose
gradient, TTV was concluded to be a non-enveloped virus (Okamoto et al., 1998b).
Furthermore, Mushahwar and coworkers have estimated by filtration that the TTV virion is
30-50 nm in diameter (Mushahwar et al., 1999). In conclusion, a new, small, non-
enveloped, ssDNA virus was found in humans.
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4 CHARACTERISTICS OF TORQUE TENO VIRUS
4.1 Genome
As the DNA of TTV was concluded to be of viral origin, it was studied further for genome
organization  and  for  transcription  properties.  The  TTV genome was  soon shown to  be  of
circular ssDNA, and to contain a GC-rich (89%-90.6%) region of 117 nucleotides (Fig. 1).
Similarities, in genome organization and in transcription regulation sites, were noticed with
chicken anemia virus (CAV), an animal pathogen of the Circoviridae family (Miyata et al.,
1999; Mushahwar et al., 1999). In addition, Mushahwar and coworkers showed with
hybridization and nuclease protection that the TTV genome is negative sense DNA, i.e.
mRNAs are produced from its complementary strand (Mushahwar et al., 1999).
Figure 1. Genome organization of TTV (reproduced from Bendinelli et al., 2001, with
permission).
The lengths of the genomes vary among TTV isolates, the average being around 3.8 kb.
(Erker et al., 1999; Hallett et al., 2000; Heller et al., 2001; Hijikata et al., 1999b; Miyata et
al., 1999; Peng et al., 2002). The genome contains a coding region of approximately 2.6 kb
and an untranslated region (UTR) of 1.2 kb. The sequence variation at the nucleotide level
is  quite  extensive  (see  below);  however,  some areas  are  conserved.  For  example  the  GC-
rich region, although varying in length (108-160 nts), is present in all the isolates (Hallett et
al., 2000; Heller et al., 2001; Peng et al., 2002). Also, a poly-A sequence downstream and a
TATA-box upstream of the coding region are conserved (Erker et al., 1999; Hallett et al.,
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2000; Heller et al., 2001; Hijikata et al., 1999b). At the nucleotide level the UTR is more
conserved than the coding area, and contains elements for transcription regulation (Kamada
et al., 2004; Miyata et al., 1999; Suzuki et al., 2004).
4.2 Transcription capacity
When the full-length sequences of TTV isolates were analyzed, 2-3 open reading frames
(ORF) were identified (Erker et al., 1999; Miyata et al., 1999; Mushahwar et al., 1999;
Okamoto  et  al.,  1998b)  (Fig.  1).  However,  it  was  not  known  whether  the  ORFs  were
transcribed. Kamahora and coworkers cloned a genotype-1 isolate in full length, transfected
it into the monkey kidney cell line Cos-1, and identified three clone-derived mRNA
species: 3.0, 1.2 and 1.0 kb in length (Fig. 2). The transcripts used the same poly-A at the
end of the coding region, and began from the same area near the TATA box. All the
transcripts showed the same splicing at the beginning of the mRNAs. The 3.0-kb mRNA
contained the complete ORF1, the 1.2-kb mRNA had a second splicing that joined ORF2 to
another ORF in the same reading frame, and the 1.0-kb mRNA also had a second splicing
that joined ORF2 to another ORF in a different reading frame (Kamahora et al., 2000). The
splice sites were found to be conserved among different genotypes (Kamahora et al., 2000;
Peng et al., 2002), and the same mRNAs were also identified in vivo in bone marrow cells
from a TTV infected subject (Okamoto et al., 2000c). Thus, it was proved that TTV uses
alternative splicing to create mRNAs for various putative proteins.
Figure 2. The three mRNA species identified in the genotype-1 transfected cells. The
dashed line represents the spliced areas (reproduced from Kamahora et al., 2000, with
permission).
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The UTR is used for transcription control; transcription factor binding sites are located in
the UTR (Miyata et al., 1999), and the promoter and enhancer elements have been mapped
within the UTR (Kamada et al., 2004; Suzuki et al., 2004). Interestingly, not all the
enhancer motifs at the UTR are conserved among the various isolates. This has been
suggested to result in different transcriptional regulation depending on host cell and/or on
TTV isolate (Kamada et al., 2004). In addition, the presence of additional splice variants
has been suggested (Leppik et al., 2007), the implications of which in TTV biology remain
to be elucidated.
4.3 Proteins
The open reading frames encoding TTV proteins are located in the complementary DNA
strand, the plus strand. ORFs are found in all  three reading frames, and they overlap with
each other (Miyata et al., 1999). Despite the sequence variability among TTV isolates, the
locations of the ORFs are conserved (Erker et al., 1999; Heller et al., 2001; Hijikata et al.,
1999b).  Initially,  it  was  thought  that  two to  three  ORFs  are  present  in  TTV (Erker  et  al.,
1999; Miyata et al., 1999; Mushahwar et al., 1999; Okamoto et al., 1998b), however,
splicing of the mRNAs yields additional transcript variants (Kamahora et al., 2000).
ORF1:  The  longest  ORF,  named  ORF1,  is  found  in  all  TTV  isolates,  and  it  has  been
suggested to encode a capsid protein (Takahashi et al., 1998). The predicted length of the
ORF1-encoded protein varies, ranging from 719-770 amino acids (Erker et al., 1999; Heller
et al., 2001; Tanaka et al., 2000b; Ukita et al., 2000). In some isolates, stop codons are
found in the middle of ORF1, shortening or interrupting the putative protein (Erker et al.,
1999; Jelcic et al., 2004; Luo et al., 2002). It has been suggested that the interrupted ORF1
could form defective viruses (Pollicino et al., 2003). The ORF1 sequence varies at the
amino acid level among TTV isolates, showing amino acid differences of the order of 50-
70% (Luo et al., 2002; Ukita et al., 2000). However, these differences are not uniformly
distributed since ORF1 contains hypervariable regions (HVRs) in which
mutations/nucleotide changes leading to amino acid changes occur more frequently than in
the remaining part of the protein (Jelcic et al., 2004; Luo et al., 2002; Mushahwar et al.,
1999; Nishizawa et al., 1999; Takahashi et al., 1998). It has been suggested that TTV could
escape immunological responses by mutating these HVRs (see below). The ORF1-encoded
protein is also assumed to be involved in replication, since ORF1 has two rolling circle
replication motifs, so called Rep-motifs, of which at least one seems to be conserved
among the majority of TTV isolates (Erker et al., 1999; Luo et al., 2002; Mushahwar et al.,
1999; Tanaka et al., 2001) In addition, the ORF1 encoded protein has an arginine-rich N-
terminus (Hijikata et al., 1999b; Mushahwar et al., 1999; Okamoto et al., 1998b; Takahashi
et al., 1998; Tanaka et al., 2001) that might have DNA-binding activity and function in
packaging of viral DNA into capsids (Erker et al., 1999). The capsid protein, VP1, of CAV
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has Rep-motifs and an arginine-rich N-terminus similar to the ORF1 encoded protein of
TTV, and is assumed to function as a replication associated protein (Niagro et al., 1998).
The TTV ORF1-encoded protein contains also potential glycosylation sites (Tanaka et al.,
2000b) that vary between isolates, and could have some effect on protein function and/or
antigenicity (Bendinelli et al., 2001; Hijikata et al., 1999b).
ORF2: The small ORF2 encodes a putative protein of approximately 200 amino acids.
However, in several genotypes a stop codon divides ORF2 into two smaller protein coding
areas, ORF2a and ORF2b. The ORF2b is less conserved in amino acid sequence than
ORF2a (Tanaka et al., 2000b; Ukita et al., 2000), however, the ORF2 (or ORF2b) has a
conserved amino acid motif, WX7HX3CX1CX5H, that is also found in the CAV protein
(Hijikata et al., 1999b; Peng et al., 2002; Tanaka et al., 2001). This conserved motif
corresponds to the protein-tyrosine phosphatase (PTPase) signature motif, and the protein
might be involved in the regulation of cellular and/or viral proteins during infection (Peters
et al., 2002).
Other ORFs: The nomenclature of the remaining other TTV proteins/open reading frames
varies to some extent among publications. The ORF3-encoded protein, i.e. ORF2/2 in this
thesis and ORF2-4 on the work of Kamahora and coworkers (Kamahora et al., 2000), of
approximately 280 amino acids, has a serine-rich domain preceded by basic amino acids at
the C-terminus (Peng et al., 2002; Tanaka et al., 2001). ORF3 encoded protein of genotype-
1a has been predicted to have similarities with the hepatitis C- virus (HCV) non-structural
protein 5A (NS5A), which is involved in cell cycle regulation and in suppression of
interferon-induced  anti-viral  resistance.  In  Cos-1  cells,  two  forms  of  the  TTV  ORF3
encoded protein were produced. It was shown that the slower-migrating form was
phosphorylated more at serine residues in the C-terminal region. However, the function of
this protein during the viral life cycle is not yet known. Phosphoproteins of other viruses
are usually involved in virus replication or in the regulation of cellular proteins, suggesting
similar functions for the TTV protein (Asabe et al., 2001).
The ORF2-5 (i.e. ORF2/3 in this thesis) -encoded protein, of approximately 280 amino
acids, has been shown to have similarities with proteins possessing transcription-factor
activity and could thus have some role in the regulation of TTV transcription (Kamahora et
al., 2000). A conserved amino acid motif, E-X8-R-X2-R-X6-P-X12-19-F-X1-L, is found in the
C-terminus of the protein (Okamoto et al., 2000b; Peng et al., 2002), with an unknown
function.
One putative protein of 105 amino acids, named TTV-derived apoptosis-inducing protein
(TAIP), has been shown to induce apoptosis in hepatocellular carcinoma cells, resembeling
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thus  the  apoptin-protein  of  CAV  which  causes  apoptosis  in  cancer  cells  (Kooistra  et  al.,
2004). However, whether this TAIP is expressed by all TTV isolates, or has some
cell/tissue-type specificity, remains to be studied.
In addition to the proteins listed, more ORFs have been suggested to arise by intragenomic
rearrangements and by alternative splicing (Leppik et al., 2007), thus potentially further
expanding the coding capacity and the variability of TTV isolates.
4.4 Structure
By filtration studies TTV has been estimated to be 30-50 nm in diameter (Mushahwar et al.,
1999). In three studies potential TTV particles have been identified. Itoh and coworkers
showed that TTV particles in sera, but not in feces, of HIV positive individuals are
complexed with IgG. Virus-like particles were detected with electron microscopy (Fig. 3)
in fecal and serum samples of patients with high viral copy numbers (108/ml) (Itoh et  al.,
2000).
Figure 3. Electron microscopy of TTV aggregates in a serum sample with a TTV level of
108 copies/ml. Scale bar, 100 nm. (Reproduced from Itoh et al., 2000, with permission.)
Zur Hausen and coworkers have identified TTV-like particles in lymphoma- and leukemia-
derived cell lines (zur Hausen et al., 2005). In addition, Leppik and coworkers have
detected virus-like particles in the Hodking’s lymphoma-derived cells transfected with a
full-length clone of TTV (Leppik et al., 2007).
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However, due to the lack of TTV-specific and well-characterized antibodies, immuno-
electron microscopy has not been performed, and therefore the TTV specificity of the
particles has not been confirmed. In addition, there is no cell system that would produce
high amounts of capsid proteins which could form virus-like particles. When these
applications are available, the appearance and fine-structure of TTV capsid can eventually
be revealed.
4.5 Replication mechanism
The exact mechanism of TTV replication is not known. It is assumed, based on similarities
with other circular ssDNA viruses, that TTV uses the rolling circle mechanism (Mushahwar
et al., 1999). To this end, other circoviruses encode special proteins with Rep-motifs which
bind to the initiation site of replication (Mankertz et al., 1998; Niagro et al., 1998). Based
on the amino acid sequence, TTV ORF1 has been shown to contain such Rep-motifs (Erker
et al., 1999; Luo et al., 2002; Mushahwar et al., 1999; Tanaka et al., 2001). In addition to
replication-associated proteins, animal circoviruses have conserved nonanucleotide
sequences, repeptitive sequences, and stem-loop structures that are involved in replication
(Mankertz et al., 2004; Niagro et al., 1998; Todd et al., 2004). The UTR of TTV also
contains potential stem-loop structures (Hijikata et al., 1999b; Mushahwar et al., 1999;
Peng et al., 2002). Whether these structures and proteins of TTV are used in viral
replication, is currently not known.
4.6 Sequence variation
Quite soon after the discovery of TTV it was shown that extensive divergence occurs
among TTV isolates, both at the nucleotide and at the amino acid level (Okamoto et al.,
1998b): divergences of e.g. 47-70% at the amino acid level have been reported (Biagini et
al., 1999; Luo et al., 2002). Interestingly, the divergence in the coding area is higher at the
amino acid than at the nucleotide level (Tanaka et al., 2000b), a situation that often is the
opposite. In phylogenetic analyses, TTVs have been found to form a large phylogenetic tree
with five major clusters (Biagini et al., 2004) (Fig. 4).
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Figure 4. Phylogenetic tree of 61 TTV isolates. The scale bar represents a genetic distance
of 5% (reproduced from Biagini et al., 2004, with permission).
The reason for and the mechanism of this extensive genomic variation are not known, and
several possibilities have been suggested. One is that TTV mutates with high frequency.
There are studies in which the nucleotide sequences from sequential samples have been
compared, showing either persistence of the same sequence for years, or alterations and
evolution of sequences within individuals (Ball et al., 1999; Biagini et al., 1999; Gallian et
al., 1999; Irving et al., 1999). An extensive mutation rate is usually not assumed to be
characteristic for DNA viruses since they often use cellular DNA polymerase(s) which,
unlike the reverse transcriptase encoded and used by RNA viruses, has strong proofreading
capacity. However, recently it was shown that ssDNA containing parvoviruses evolve with
a rate comparable to RNA viruses. It was suggested that this high mutation rate could be
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associated with the single-stranded nature of the genome and/or the coding capacity for
proteins involved in replication (Shackelton et al., 2006). It is thus possible that TTV has a
similar mechanism that allows it to mutate at a high rate. The majority of amino acid
changes in closely related TTV sequences have been located in the HVRs of ORF1, and it
is thus suggested that TTV circulates within individuals as quasispecies. By mutating
HVRs, TTV could evade immune responses and establish persistent infections (Jelcic et al.,
2004). It has also been suggested that only a minor fraction of the TT-viruses has all the
components required for successful infection, or that co-infection of isolates brings the
necessary components together (Khudyakov et al., 2000; Luo et al., 2002). Such
phenomena are known with other viruses: e.g. HIV is known to produce large amounts of
viruses of which some, but not all, are capable for productive infection, and plant-infecting
nanoviruses  require  several  different  virus  particles  to  co-infect  the  same  cell  until  the
production of progeny virions occurs.
One common mechanism for viruses to create new variants is recombination, and with
TTV such events have been estimated to occur quite frequently (Manni et al., 2002;
Worobey, 2000). However, Jelcic and coworkers question whether the observed
recombinations could be due to PCR artefacts (Jelcic et al., 2004), while Worobey (2000)
reports that the observed recombinations were not PCR-derived (Worobey, 2000).
Recently, also intragenomic rearrangements have been suggested to contribute to the
genomic variation of TTVs (Leppik et al., 2007).
In general, viruses evolve by producing large numbers of descedants and by generating
large numbers of mutants during replication. In addition, recombinations and reassortments
(of segmented genomes) contribute to viral evolution. Evolution, however, can not proceed
without limitations, e.g. capsid size limits the amount of packaged genetic material. In
addition, extensive mutations can lead to non-viable viruses with lost protein functions,
some of which the virus needs to conserve in order to replicate within its host cells.
Furthermore,  an  excessively  virulent  virus  kills  its  host  and  thus  itself.  The  ultimate  goal
for a virus would be to achieve such a balance with its host that it can replicate and
reproduce itself without causing the host to die (too soon).
As for TTV, the virus has been suggested to have co-evolved with us for millions of years,
resulting in extremely wide variation (Ball et al., 1999; Biagini et al., 1999; Gallian et al.,
2000; Hijikata et al., 1999b; Prescott et al., 1999). The heterogeneity of TTVs at the
nucleotide level could be due to a low replication rate, generation of mutations, a long
history of human infections, low genetic fitness, and/or lack of competition between
isolates (Khudyakov et al., 2000). In addition, frequent recombination events could
smoothen the differences between virus populations (Manni et al., 2002). Whatever the
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mechanism behind the heterogeneity of TTV is, it is evident that humans are not infected
by a signle TTV species, but by a large family of TT viruses.
5 PREVALENCE OF TORQUE TENO VIRUS
5.1 TTV DNA prevalence in blood
After identification of the new virus infecting humans, it became crucial to determine its
prevalence among healthy individuals, and especially in various patient groups for possible
disease associations. TTV DNA prevalence was estimated to be low initially at a time when
its wide sequence variation was not known. The PCR conditions, and especially the primers
used in research, differed significantly, some detecting fewer genotypes than others,
resulting in discrepancy (Ali et al., 2002; Irving et al., 1999; Leary et al., 1999; Lopez-
Alcorocho et al., 2000; Niel et al., 1999; Nishiguchi et al., 2000; Okamoto et al., 1999b;
Pollicino et al., 2003; Ukita et al., 2000). To date, with knowledge of the genomic
variation, various primer combinations have been tested to develop a PCR method which
would detect, quantitate, and/or differentiate all the TTV genotypes and TTV-like viruses
(Biagini et al., 2001a; Devalle et al., 2004; Hu et al., 2005; Maggi et al., 2003b; Moen et
al., 2002b). In addition, new sequence-independent methods, like rolling circle
amplification, have been used for amplification of divergent, and new, TTV isolates
(Biagini et al., 2007; Niel et al., 2005).
Regardless of the technical issues, it became soon apparent that TTV occurs worldwide in
the general population (Abe et al., 1999; Okamoto et al., 1999b; Prescott et al., 1998;
Viazov et al., 1998a) and that its prevalence increases with age (Hsieh et al., 1999; Saback
et al., 1999; Umemura et al., 2001a; Zhong et al., 2001a). The reported DNA prevalences
vary, depending on the PCR methods used, but in general are very high: for example TTV
DNA positivity in sera of blood donors is 46-62% in Brazil (Devalle et al., 2004; Niel et al.,
1999) 51.6-82.7%  in Turkey (Erensoy et al., 2002; Yazici et al., 2002), 90% in Norway
(Huang et al., 2001), and 53.3% in China (Zhong et al., 2001a). Variation in geographical
prevalence of some genotypes, or evolution of genotypes within isolated ethnic groups has
been suggested to occur (Prescott et al., 1999; Umemura et al., 2003; Vasconcelos et al.,
2003. However, results showing no geographical differences in TTV DNA prevalence or
genotype/genogroup prevalence have also been presented (Gallian et al., 2000; Huang et
al., 2001; Manni et al., 2002; Mushahwar et al., 1999; Pisani et al., 1999). Some
genogroups are suggested to be more common than others (Maggi et al., 2005a; Maggi et
al., 2006), but this might reflect the use of suboptimal primers or some viral characteristics
of these genogroups. In addition, the fluctuating and/or low virus loads could account for
variation in results under slightly suboptimal PCR conditions (Huang et al., 2001).
Review of the literature
25
The knowledge of TTV prevalence changes all the time. New variants are discovered and
new methods are developed (Biagini et al., 2007; Niel et al., 2005). What is the true
representation of TTV in humans is an important topic of forthcoming studies.
Nevertheless, it is obvious that this virus (or these viruses) is frequently (or constantly)
present in blood of the majority of healthy individuals.
5.2 TTV DNA prevalence in tissues and body fluids
By PCR methods, TTV DNA has been detected in several organs, cells and body fluids,
including peripheral blood mononuclear cells (PBMC), saliva, urine, feces, throat swabs,
liver, bile, cervical swabs, semen, hair, skin, bone marrow, lymph node, muscle, thyroid
gland, lung, spleen, pancreas, kidney, cerebrospinal fluid, gastrointestinal tract, and brain
(Chan et al., 2001a; Deng et al., 2000; Fornai et al., 2001; Gallian et al., 2000; Inami et al.,
2000a; Ishikawa et al., 1999; Jiang et al., 2000; Lopez-Alcorocho et al., 2000; Maggi et al.,
2001a; Maggi et al., 2003a; Martinez et al., 2000; Matsubara et al., 2000; Okamoto et al.,
1998b; Okamoto et al., 1999a; Okamoto et al., 2001a; Okamura et al., 1999; Osiowy et al.,
2000; Pollicino et al., 2003; Rodriguez-Inigo et al., 2000; Ross et al., 1999; Sospedra et al.,
2005; Suzuki et al., 2001; Ukita et al., 1999; Yamamoto et al., 1998; Yu et al., 2002; Zhong
et al., 2002). It seems that there is no preference for a given genotype to exist in certain
tissues (Nakagawa et al., 2000; Pollicino et al., 2003). The PBMC contains several subsets
of different cells,  and the TTV DNA in PBMC seems to show no restriction to a specific
cell type: it is found in B-lymphocytes, T-lymphocytes, monocytes, polymorphonuclear
leukocytes, granulocytes, and in natural killer cells, but not in red blood cells or platelets
(Maggi et al., 2001b; Takahashi et al., 2002). There are also contradictory results on the
presence of TTV DNA in B-lymphocytes (Garbuglia et al., 2003) and in T-lymphocytes
(Yu et  al.,  2002).  Besides  TTV DNA,  TTV mRNA has  been  detected  at  least  in  PBMC,
cerebrospinal fluid, breast, colon, omentum, gallbladder, liver, bone marrow and thyroid
(Mariscal et al., 2002; Okamoto et al., 2000c; Pollicino et al., 2003).
In  addition  to  normal  tissues,  TTV  DNA  has  been  detected  in  tissues  of  several  cancer
types (de Villiers et al., 2002), including brain tumors (Sospedra et al., 2005). However, as
noted by Takahashi and coworkers, since TTV is present in the cells of the immune system
that invade multiple tissues with inflammation, it should be carefully determined whether
TTV really harbours the cells inherent in particular tissue (Takahashi et al., 2002).
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6 TORQUE TENO VIRUS-LIKE VIRUSES
6.1 Torque teno minivirus
During the ten years since the discovery of TTV, TTV-like viruses have also been
identified in humans. TTV-like minivirus, TLMV (later termed Torque teno minivirus,
TTMV), was found in a TTV-viremic serum by serendipity; the primers and PCR
conditions that were used favored amplification of TTMV instead of TTV (Takahashi et al.,
2000).  The  genome  of  TTMV  consists  also  of  circular  negative  sense  ssDNA  of
approximately 2800-2900 nucleotides, i.e. is shorter than that of TTV. The particle size of
TTMV has been estimated to be less than 30 nm, going below TTV also in diameter
(Takahashi et al., 2000).
TTMV resembles TTV in genomic structure, possessing the GC-rich region and the coding
area. TTMV also contains a CAV-like motif in the ORF2 region, and an ariginine-rich N-
terminus as well as Rep-motifs in the ORF1 (Biagini et al., 2001b; Takahashi et al., 2000).
The ORF2 protein has been shown to act as a dual-specificity phosphatase (Peters et al.,
2002). ORF3 was shown to have a serine-rich C-terminus, exhibiting some homology with
a topoisomerase I protein and thus potentially being involved in the replication process
(Takahashi et al., 2000).
TTMV is also highly divergent; the first three TTMV sequences discovered differed from
each other by 42% at the nucleotide level, and by 67% at the amino acid level (Takahashi et
al., 2000). Phylogenetically TTMV, as well as TTV, forms a large family or cluster of
isolates (Niel et al., 2001) that diverge from each other as much as 47% within the ORF1
area (Biagini et al., 2006b; Biagini et al., 2007) (Fig. 5). The mechanism for this divergence
is not known, but similar recombination-prone sites as in TTV have been postulated to exist
(Biagini et al., 2001b).
TTMV is distributed worldwide among healthy individuals without (apparent) geographical
clustering (Biagini et al., 2001b; Niel et al., 2001). For example, in sera of blood donors the
TTMV DNA prevalence is 62% in France (Biagini et al., 2006b), 67-72% in Brazil
(Devalle et al., 2004; Niel et al., 2001), and 48% in Norway (Moen et al., 2002a). TTMV
isolates have been shown to occur in various tissues, such as plasma/serum, PBMC, feces,
saliva, bone marrow, spleen and cervical swabs, in varying viral loads (1.3x103-1.7x108
copies per g of DNA) (Biagini et al., 2001b; Fornai et al., 2001; Thom et al., 2003;
Vasconcelos et al., 2002).
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6.2 Small anellovirus and Torque teno midivirus
Small anelloviruses (SAV), were found by the DNase-SISPA method in patients with an
acute viral infection syndrome (Jones et al., 2005). SAVs also share the genomic structure
of other TTVs; a GC-rich region and a coding region are found in their genomes that are of
2249-2635 nt in length (Jones et al., 2005). The SAV ORF2 area was shown to possess a
similar CAV-like motif as in the other TTVs (Andreoli et al., 2006). Similar to TTVs, SAV
isolates seem to form a large phylogenetic tree (Fig. 5), showing genomic variation of up to
41%. SAV isolates have also been found in various tissues, including saliva and PBMC
(Biagini et al., 2006a) as well as in nasopharyngeal aspirates (Chung et al., 2007). As other
TTVs,  SAVs  are  common  among  healthy  inividuals;  they  occur  e.g.  in  20%  of  French
blood donors (Biagini et al., 2006a) and in 34.5% of Korean children (Chung et al., 2007).
In addition, isolates related to SAV, but with even shorter genomes (2002 nt and 2454 nt)
have been identified. They differed from SAVs by approximately 40%, forming a cluster of
their own within the SAV sequences (Biagini et al., 2007).
Figure 5. Phylogenetic tree constructed from ORF1 sequences of TTVs, TTMVs and
TTMDVs (marked as MDx-xxx) (Adapted from Ninomiya et al., 2007, with permission).
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Recently Ninomiya and coworkers reported, while attempting to amplify SAV sequences in
sera, amplicons longer than expected. The full-length clones were of 3242-3253 nt, with all
the characteristics of TTV-like viruses. Most importantly, the previously described SAVs
were  reported  to  be  deletion  mutants  or  artefacts  generated  during  amplification  of  these
longer isolates. These newly identified isolates were termed Torgue teno midiviruses
(TTMDV) (Ninomiya et al., 2007a). Upon analyzing more TTMDV sequences, the authors
noticed that these formed a large swarm of isolates differing in length (3175-3230 nt) and
in sequence (33% divergence at nucleotide level and 60.7% at amino acid level of ORF1)
(Fig. 5). In addition to other TTV-like characteristics, also three Rep-motifs were identified
in the ORF1 region, as well as putative stem-loop structures in the GC-rich region. Based
on this study, TTMDVs occur in at least 40% of nonsymptomatic individuals (Ninomiya et
al., 2007b), i.e. apparently ubiquitously worldwide.
It has been speculated that these smaller TTVs could be the result of intragenomic
rearrangements of full-length TTVs (Leppik et al., 2007). However, in the original
investigation TTMV was clearly demonstrated not to be a satellite genome of TTV, but a
complete virus (Takahashi et al., 2000). It is highly probable that with new amplification
methods, additional variants of TTV will be discovered, thus continuing the expansion of
the phylogenetic tree (Fig. 5).
6.3 Torque teno viruses of animals
TT-viruses are not restricted to humans, and various animal species have been shown to
carry their own TTVs. Non-human primates are infected with simian TTV, showing a high
DNA prevalence (Abe et al., 2000; Cong et al., 2000; Okamoto et al., 2000a; Romeo et al.,
2000; Thom et al., 2003). The genomic organization of simian TTVs is similar to that of
human TTVs (Inami et al., 2000b; Okamoto et al., 2000b), and co-evolution of TTVs with
their hosts has been suggested (Thom et al., 2003).
Pets also have been shown to have TTVs. For example several isolates have been found in
cats and dogs (Biagini et al., 2007; Okamoto et al., 2002). In addition, other mammals, such
as tupaias (Okamoto et al., 2001b) and pigs have species-specific TT viruses (McKeown et
al., 2004; Niel et al., 2005; Okamoto et al., 2002). The swine TTV has been shown to form
at least two genogroups (Niel et al., 2005) that are found worldwide in pigs (Kekarainen et
al., 2006; McKeown et al., 2004). The high prevalence of swine TTV raises a possible risk
in xenotransplantation for immunosuppressed organ recipients (McKeown et al., 2004).
Interestingly, genogroup 2 was found more often than genogroup 1 in pigs with post-
weaning multisystemic wasting syndrome, the meaning of which remains to be studied
(Kekarainen  et  al.,  2006).  Whether  all  animals  have  species-specific  TT  viruses,  remains
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investigated. However, based on the current information on this virus family, it would not
be surprising to find TT viruses in all animal species.
7 TAXONOMY OF VIRUSES
The  International  Committee  on  Taxonomy  of  Viruses  (ICTV)  maintains  the  universal
taxonomy, i.e. classification, of viruses. The classification of viruses varies depending on
our knowledge of the particular virus: the demarcation for species within the same genus
can be based on structure, genome, host organism, mode of transmission, or other
properties common to all the viruses within that species. The definition for a virus species
is “a polythetic class of viruses that constitute a replicating lineage and occupy a particular
ecological niche”. The virus species form genera, which constitute families that are
universal classes, the members of which have to share key properties (e.g. circular ssDNA
genome and infect vertebrates) (Ball, 2004)
(http://www.virustaxonomyonline.com/).
7.1 Taxonomy of TTVs
Before TTV was known to have a circular genome, it was thought to represent a new
parvovirus, i.e. a ssDNA virus with a linear genome (Okamoto et al., 1998b). When the
circular  nature  of  TTV  genome  was  revealed,  TTV  was  concluded  to  closely  resemble
CAV, a member of the Circoviridae family, in genome organization. Thus it was proposed
that TTV could be the first circovirus found in humans (Miyata et al., 1999; Takahashi et
al., 1998), or  that TTV could form a new virus family (Mushahwar et al., 1999). When the
TTMV was discovered, it was proposed to be an intermediate between CAV and TTV, and
it  was  suggested  that  all  these  three  viruses  could  be  evolutionarily  linked  and  classified
into a new virus family (Takahashi et al., 2000).
It now seems that the TTV genotypes form a phylogenetic tree with five major clusters
(Figs. 4 and 5) (Biagini et al., 2004; Peng et al., 2002). Jelcic and coworkers have
suggested that the TTV isolates could form a new virus family with a subdivision into
genera, species, types, subtypes and variants based on the sequence divergence (Jelcic et
al., 2004). In addition to TTV and TTMV, the recently identified SAVs/TTMDVs shall also
be included in the classification. These three virus species consist each of a wide repertoire
of isolates with sequence divergences within the whole genome of at least 50%, 40% and
33%, respectively (Ninomiya et al., 2007b). In addition, when the role of the smaller,
rearranged TTVs (Leppik et al., 2007) is fully revealed, the genotyping of TTVs might
further change.
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To date, TTV and TTV-related isolates are officially classified as a floating genus
Anellovirus (Biagini et al., 2004), yet the nomenclature of isolates and genotypes still
varies within publications. Based on a collaborative work, it has been proposed by
Circoviridae-Anellovirus Study Groups of ICTV that all the anellovirus members (TTV,
TTMV, SAV/TTMDV, and highly divergent animal isolates) could be classified into a new
viral family, Anelloviridae. By phylogenetic analysis of the entire ORF1 of anellovirus
isolates, the family would have several genera with species and subspecies
(http://www.ictvonline.org/index.asp?bhcp=1) (Biagini et al., taxonomic proposal ICTV
Report, unpublished data). It has also been foresightedly suggested that since CAV has
several similarities to TTVs (i.e. mRNA splicing, genomic organization etc.), CAV and
anelloviruses could be included into the same virus family, but within their own
subfamilies (Biagini et al., unpublished data).
7.2 Family Circoviridae
The known vertebrate infecting circular ssDNA viruses are found only in the family
Circoviridae. Other viruses with circular ssDNA genomes include bacteria-infecting
Microviridae and Inoviridae, and plant-infecting Geminiviridae and Nanoviridae (ICTVdB
- The Universal Virus Database, version 4.) (Fauquet et al., 2004). It has been suggested
that circoviruses have evolved from plant nanoviruses, which switched host from plant to
vertebrate, subsequently recombining probably with calicivirus, establishing a new virus
lineage, circoviruses (Gibbs et al., 1999).
Within the family Circoviridae (Fig. 6) chicken anemia virus is classified into the genus
Gyrovirus, and porcine circovirus (PCV) and beak and feather disease virus (BFDV) into
the genus Circovirus (Pringle, 1999). All the viruses within the family Circoviridae have a
circular ssDNA genome, but they differ in structure (Crowther et al., 2003) (Fig 7.) and in
genomic organization (ambisense vs. antisense). Circoviruses replicate via double-stranded
DNA intermediate that is used as a template for the generation of viral ssDNA by the
rolling circle mechanism. For replication, viruses use the host cell DNA polymerase in the
S phase of cell division. The infections are highly prevalent worldwide, and are transmitted
feco-orally and vertically. Circoviruses cause subclinical infections in their animal hosts,
but are also associated with various diseases, caused by infection-related lymphoid
depletion and immunosuppression (Todd et al., 2004).
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Figure 6. Phylogenetic tree based on Rep protein sequences of the family Circoviridae.
(Reproduced from Todd et al., 2004, with permission.)
Figure 7. Three-dimensional drawings of circoviruses, based on computational analysis of
electron micrographs: (from left to right) CAV, PCV-2, and BFDV. (Adapted from
Crowther et al., 2003, with permission).
Genus Circovirus
Viruses in the genus Circovirus have ambisense genomes, i.e. the viral proteins are
encoded both in sense and anti-sense orientation, resulting in multiple mRNAs (Bassami et
al., 1998; Cheung, 2003a; Cheung, 2003b; Niagro et al., 1998).
Porcine circovirus (PCV)  has  two  strains  (PCV1  and  PCV2)  with  divergence  of
approximately 20%, of which PCV2 is pathogenic and causes post weaning multisystemic
wasting syndrome (PMWS) in pigs (Hamel et al., 1998; Meehan et al., 1998). The PCV
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genome is approximately 1760 nt long and contains a conserved nonanucleotide motif in
the potential stem-loop structure that is used for initiation of replication (Todd et al., 2004).
The ORF2-encoded virus protein is the only protein forming the capsid (Nawagitgul et al.,
2000). ORF1-encoded replication associated protein, Rep (Mankertz et al., 1998), is
produced in two forms by alternative splicing (Mankertz et al., 2001; Mankertz et al.,
2004).
Beak and feather disease virus (BFDV) infects young psittacines and causes persisting
lymhoid depletion predisposing the birds to secondary infections with potentially lethal
pathogens (Todd et al., 2004). In addition to BFDV, various avian circoviruses are included
in the genus [ICTVdB - The Universal Virus Database, version 4.; (Todd et al., 2004)]. The
avian-infecting circoviruses have genomes of approximately 1800-2000 nt, and are
distributed widely in various tissues, frequently causing sub-clinical infections. Viral loads
have been suggested as a correlate to disease severity (Niagro et al., 1998; Todd et al.,
2004)
Genus Gyrovirus
Chicken anemia virus (CAV)  is  the  sole  member  of  the  genus Gyrovirus (Todd  et  al.,
2004). CAV has a genome of 2300 nt in anti-sense organization, i.e. the proteins are
encoded from one direction on the complementary DNA-strand (Noteborn et al., 1991;
Noteborn et al., 1992; Todd et al., 1990). Until recently it was thought that CAV encodes
one long polycistronic mRNA (Noteborn et al., 1992; Phenix et al., 1994), however,
Kamada and coworkers showed CAV to generate by alternative splicing at least three
mRNA species, similar to TTV (Fig. 8). The previously described unspliced mRNA is also
produced, and the meaning for the CAV life cycle of the three spliced mRNA species
remains to be elucidated (Kamada et al., 2006).
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Figure 8. The transcription map of CAV. (Reproduced from Kamada et al., 2006, with
permission).
VP1 is the only protein forming the capsid of CAV, however, VP2 co-expression is
required for generation of neutralizing antibodies, VP2 probably acting as a scaffold protein
and providing proper folding to VP1 (Noteborn et al., 1998; Todd et al., 1990). VP1
possibly also acts in replication since the Rep-motifs occur within (Todd et al., 2004). VP3,
called Apoptin, causes apoptosis in infected cells (Noteborn et al., 1994; Noteborn, 2004).
This Apoptin-induced apoptosis occurs selectively also in human cancer cells, and Apoptin
has been investigated for therapeutic potential (Danen-Van Oorschot et al., 1997; Noteborn,
2004). VP2 acts as a dual-specificity protein phosphatase, as does ORF2 protein of TTMV
(Peters et al., 2002), the activity of which is required for replication, cytopathogenicity, and
MHC-I down regulation in infected cells (Peters et al., 2005; Peters et al., 2006). CAV
seems  to  have  two  strains  (ICTVdB  -  The  Universal  Virus  Database,  version  4.),  with  a
divergence of ~4% (Natesan et al., 2006).
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CAV induces immunosupression in chickens by depleting hemocytoblasts and thymocytes
(Miller et al., 2004) by apoptosis (Jeurissen et al., 1992). In addition, CAV infection causes
impairment in development of pathogen specific cytotoxic T-cells, and leads to more severe
diseases in co-infection with other pathogens (Markowski-Grimsrud et al., 2003). The
clinical symptoms depend on the age of the infected chicken, on the presence of antibodies,
and on the presence of secondary infections. Chickens of all ages are prone to infection, but
clinical disease develops only in young or in immunosuppressed chickens. In addition,
CAV can establish latent infection in reproductive tissues from which it is activated at the
time of reproductive maturation (Miller et al., 2004).
8 TRANSMISSION, INFECTION AND HOST CELLS OF TORQUE TENO
VIRUS
Viruses have various ways of transmission. For example HIV is transmitted via blood,
influenza virus via aerosols, caliciviruses often via water, and TBE via ticks. These forms
of passive physical transport or live vectors eventually bring the virus into contact with its
target cell, and the viral life cycle can begin. The virus is said to have infected its host when
it has entered the target cell. Viruses can cause acute, latent, or persistent infections. Acute
infections, and acute phases of chronic infections, are usually short-lived: virus hits the
target and escapes before the host dies or elicits a strong immune response. Latent
infections often last for life: the virus hides inside the cells, either as an episome or as
integrated into the host genome, and avoids the immune response. Under certain
circumstances the virus is rescued and starts to produce progeny virions. Persistent
infections (including chronic infections) last for a long time, either due to low virus
production, or due to viral infection of confined body compartments, or due to dysfunction
of the host’s immune system.
8.1 Transmission of TTV
Since TTV has been found in a myriad of tissues and body fluids (see section “Prevalence
of  Torque  teno  virus”)  several  transmission  routes  are  possible.  Due  to  the  emergence  of
TTV in post-transfusion hepatitis, blood and blood products have been thoroughly
investigated for the source of TTV infection. Indeed, TTV DNA prevalence has been
shown to be higher in patients having received several blood transfusions or blood products
(Forns et al., 1999; Maeda et al., 2000; Prati et al., 1999; Simmonds et al., 1998; Viazov et
al., 1998b), although there are also results that do not support this (Rubinstein et al., 2000;
Schröter et al., 1998). In addition, TTV has been found in various blood products, including
first-generation recombinant factor VIII concentrates, factor IX concentrates (Azzi et al.,
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2001; Simmonds et al., 1998; Yokozaki et al., 1999), and intramuscular immunoglobulin
batches (Pisani et al., 1999). In addition to TTV, TTMV could potentially be transmitted
via blood transfusions (Takahashi et al., 2000). Blood borne viruses, such as HIV, are
transmitted among drug users via shared needles. However, it has been shown that this is
not the main route for TTV transmission (MacDonald et al., 1999; Yazici et al., 2002). Due
to the transmission via blood, some research groups have called TTV a “transfusion
transmitted virus”. However, this nickname is misleading because TTV most probably is
transmitted via other routes as well.
Transmission  via  blood  does  not  explain  the  prevalence  of  TTV  worldwide.  Most  of  the
other viruses showing high prevalence at the population level are usually efficiently
transmitted via the feco-oral route. This most probably is also the case with TTV, since the
virus is found in feces (Okamoto et al., 1998a; Ross et al., 1999; Ukita et al., 1999), even
among 7-12 month-old healthy children (Lin et al., 2000).
Viruses are transmitted via food and water. As is typical for a highly prevalent virus, TTV
is found in various aquatic environments. TTV was detected in 5% of surface water
samples from a river in Japan (Haramoto et al., 2005a), as well as in waste water
(Haramoto et al., 2005b; Vaidya et al., 2002). In addition, TTV and TTMV were detected
in 8% of Norwegian shellfish (Myrmel et al., 2004), indicating that TTV is present in
water.
Viruses are also effectively spread by droplets. Indeed, higher TTV loads detected in saliva
than  in  serum (Deng et  al.,  2000;  Gallian  et  al.,  2000),  presence  of  TTV in  throat  swabs
(Ishikawa et al., 1999), and detection of SAVs in nasopharyngeal aspirates (Chung et al.,
2007) suggest that spreading via the respiratory tract and droplets could be one
transmission route for TTV.
Sexual transmission is another important way for a virus to spread within the adult
population. TTV has been found in cervical swabs (Calcaterra et al., 2001; Chan et al.,
2001c; Fornai et al., 2001) and in semen (Inami et al., 2000a; Martinez et al., 2000)
suggesting sexual transmission. However, this mode of transmission has been proposed to
be of minor importance (MacDonald et al., 1999; Salakova et al., 2004; Yazici et al., 2002).
It seems that humans acquire TTV infection(s) very early in life. TTV DNA has been
detected in blood of newborns, in cord blood, and in amniotic fluid, suggesting
transmission already in utero (Bagaglio et al., 2002; Gerner et al., 2000; Matsubara et al.,
2001; Morrica et al., 2000; Saback et al., 1999). In addition, newborns acquire TTV from
the environment within a few months (Davidson et al., 1999; Kazi et al., 2000). This
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environmentally acquired infection could be transmitted from the mother, since TTV has
been found in breast milk (Gerner et al., 2000; Iso et al., 2001; Matsubara et al., 2001; Ohto
et al., 2002; Schröter et al., 2000). Also, results contradictory to in utero transmission have
been  presented,  showing  TTV  DNA-negative  cord  blood  samples,  and  TTV  DNA
appearance from a few months of age upwards (Davidson et al., 1999; Hsieh et al., 1999;
Iso et al., 2001; Kazi et al., 2000; Ohto et al., 2002; Salakova et al., 2004; Simmonds et al.,
1999; Sugiyama et al., 1999). However, the absence of TTV DNA could be due to the PCR
methods used (Matsubara et al., 2001), and due to possibly low virus load in infants. When
TTV sequences from children and from mothers have been compared, they show both
similar and divergent sequences, indicating both mother-child transmission and
environmental transmission (Bagaglio et al., 2002; Davidson et al., 1999; Lin et al., 2002;
Ohto et al., 2002; Sugiyama et al., 1999). Also, TTMV has been detected in cord blood,
amniotic fluid, breast milk and newborn sera, with sequence similarity to those of the
mothers (Matsubara et al., 2001). For HBV it has been shown, that in hyper-endemic areas
perinatal and early-life horizontal transmission of the virus results in high prevalence and a
chronic carrier stage (Custer et al., 2004). The mother-to-child transmission route could in
part explain the high prevalence and persistent infectious characteristics for TTV.
It is quite obvious that such a prevalent virus group as anelloviruses may have several
modes of transmission; feco-oral and droplet spread being at the moment the most probable
candidate routes.
8.2 TTV infections in animals
Animal models are still very important in the research of virus transmission and infections.
Rhesus monkeys and chimpanzees can be infected orally or intravenously with human TTV
originating from human feces and/or serum, indicating presence of infectious TTV and
transmission to animals (Luo et al., 2000; Mushahwar et al., 1999; Okamoto et al., 2000a;
Romeo et al., 2000; Tawara et al., 2000). In Rhesus monkeys, a few days post-infection, the
virus was detected in liver (in the nuclei and/or cytoplasm of hepatocytes), and was
excreted in bile, feces, and blood. Chronic infection was sustained for at least six months.
The infection could be passaged to other monkeys, with no significant nucleotide changes,
thus indicating stability of the replicating TTV sequence (Luo et al., 2000). In chimpanzees,
TTV was detected transiently in the sera, with no signs of hepatitis (Mushahwar et al.,
1999). In another study, both transient and persistent infections in chimpanzees were
observed, with mild biochemical and histological changes in liver (Tawara et al., 2000).
The difference between those two experiments could be due to the TTV loads in the
inoculums or due to the amount of immunocomplexes (inoculum from persistent infection
with more immunocomplexes in the former study, and from acute infection with less
immunocomplexes in the latter) (Tawara et al., 2000). To further support the
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transmissibility of human TTVs to animals, human TTV sequences have been identified in
samples obtained from captive chimpanzees and from animals used for transmission studies
of human viruses (Cong et al., 2000; Okamoto et al., 2000b; Romeo et al., 2000). TTV
sequences identified in gibbons bred in captivity were found to be closely related to human
sequences, and the virus was hypothesized to have been transmitted to gibbons from the
animal handlers (Noppornpanth et al., 2001).
Interestingly, simian-TTV infections occur also in humans, whereby TTV has been
postulated  to  be  of  zoonotic  origin  (Iwaki  et  al.,  2003).  However,  it  is  also  possible  that
some TTVs found in apes and classified as simian-TTVs are actually human, as transmitted
during capture, transportation or handling of the animals, as has been speculated for human
TTV sequences detected in gibbons (Noppornpanth et al., 2001). Furthermore, zoonotic
origin alone would not fulfill the worldwide occurence of TTV in humans. Nevertheless, it
is possible that animals could, in part, serve as reservoirs of human TTV. This scenario is
supported by the results showing human TTVs in farm animals such as chickens, pigs,
cows and sheep (Leary et al., 1999) and in camels in the United Arab Emirates (Al-Moslih
et al., 2007), but others have not been able to verify the results on farm animals, leaving
this scenario unresolved (Thom et al., 2003).
8.3 TTV infections in humans
In the first TTV publication by Nishizawa and coworkers, TTV infections in humans were
shown  to  be  either  transient  or  persistent  (Nishizawa  et  al.,  1997).  The  time  course  (i.e.
kinetics) of TTV infections has been studied in various patient groups. TTV viremia has
been shown to persist for several years (Azzi et al., 2001; Ball et al., 1999; Biagini et al.,
1999; Irving et al., 1999; Lefrere et al., 2000; Sugiyama et al., 1999), but also clearance of
the virus has been detected (Ohto et al., 2002; Prati et al., 1999; Simmonds et al., 1998;
Wilson et al., 2001). One reason for the variable results in the acute vs. persistent infection
could be fluctuation of virus levels. In persisting infections, the DNA sequence has been
shown to  either  remain  unchanged,  or  change  with  time (Ball  et  al.,  1999;  Biagini  et  al.,
1999; Irving et al., 1999) indicating true persistence, superinfections, and/or evolution of
quasispecies. TTV infection has been suggested to be a very dynamic process: it has been
estimated that over 90% of the virions are cleared every day, with generation of 3.8x1010
virions to replace the cleared ones (Maggi et al., 2001c).
In general, the levels of TTV viremia in healthy subjects are assumed to be low, and in
comparison with cancer patients, the viral levels in PBMC were shown to be two logs
lower (Zhong et al., 2001b). In addition, it has been shown that among the study subjects
the  levels  of  TTV  DNA  either  remain  steady  or  fluctuate,  in  the  range  of  102 to  108
copies/ml (Ball et al., 1999; Maggi et al., 2005b; Pistello et al., 2001; Zhong et al., 2001a).
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However, all these results have been obtained in variable study populations with PCR
methods which are affected by the presence of several isolates in fluctuating levels, and
thus the interpretation of results is difficult.
Co-infections with multiple TTV genotypes are common, even in healthy individuals (Ball
et al., 1999; Biagini et al., 1999; Chan et al., 2001a; Forns et al., 1999; Gallian et al., 1999;
Jelcic et al., 2004; Mushahwar et al., 1999; Niel et al., 2000; Okamoto et al., 1999b;
Prescott et al., 1999; Takayama et al., 1999b). The presence of mixed infections could 1)
infer that TTV is not cleared from the system, 2) that re-infections and super-infections
occur frequently, 3) that the virus is spread via several routes, 4) that the mutation rate is
high, and/or 5) that a previous infection does not protect against a re-infection (White et al.,
2000). Of these possibilities, at least infections with new genotypes have been documented
to occur during follow-up (Gallian et al., 1999; Maggi et al., 2006). In addition to mixed
infections with various TTV genotypes, mixed infections with several TTMV isolates
(Vasconcelos  et  al.,  2002),  as  well  as  co-infections  with  TTMV  and  TTV  have  been
reported to occur in healthy individuals (Biagini et al., 2006b; Moen et al., 2002a; Niel et
al., 2001; Vasconcelos et al., 2003). Also co-infections with the three anelloviruses (TTV,
TTMV and SAV/TTMDV) have been reported (Biagini et al., 2006a; Ninomiya et al.,
2007a).
Whether the recently identified rearranged sub-genomic fragments (Leppik et al., 2007)
will further make the picture of anellovirus infections more complex remains to be seen. In
any case, data of sewage waters suggest that there are no seasonal changes in TTV
infections (Haramoto et al., 2005b; Vaidya et al., 2002), i.e. it seems that we acquire TTV
throughout the year and throughout our lives.
8.4 TTV host-cell tropism
The presence of TTV DNA in several organs and tissues suggests a wide host cell tropism.
A search for the host cell for TTV has been attempted by showing the location of TTV
DNA (in situ methods or DNA quantification) in certain cells, or by detecting replicating
TTV DNA in tissues.
Cells circulating in blood and originating from the hematopoietic compartment have been
the strongest candidates for TTV host cells, and the presence of TTV in PBMC has been
confirmed by fluorescent in situ hybridization (Lopez-Alcorocho et al., 2000; Mariscal et
al., 2002; Zhong et al., 2002). Since the TTV sequences found in serum were different from
those in PBMC, it has been suggested that some genotypes could have preference for
PBMC (Chan et al., 2001a; Okamoto et al., 1999a; Okamoto et al., 2000d). In addition,
since the sera of some PBMC-positive patients were TTV DNA negative, it has been
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suggested that PBMC could serve as a reservoir for TTV (Garbuglia et al., 2003; Maggi et
al., 2001c). Furthermore, PBMC can be infected with TTV (Zhong et al., 2002), and when
stimulated, produce infectious TTV (Maggi et al., 2001b; Mariscal et al., 2002). Bone
marrow contains precursors for hematopoietic cells. The notion of decreasing levels of
TTV-DNA in bone marrow transplant recipients during myelosuppression led to a
suggestion that hematopoietic cells could sustain TTV replication (Kanda et al., 1999).
Further evidence, showing replication of TTV in bone marrow cells (Yu et al., 2002; Zhong
et al., 2002) and clearance of TTV after bone marrow transplantation (Chan et al., 2001b),
strengthen the possibility that the hematological compartment could be the site of
replication and/or persistence of TTV.
The presence of high TTV-DNA levels in saliva (Lopez-Alcorocho et al., 2000; Okamoto
et al., 1998b; Rodriguez-Inigo et al., 2000; Suzuki et al., 2001) has led to investigations of
oropharyngeal tissue and/or salivary glands as a putative target/host tissue for TTV
infection (Deng et al., 2000). Indeed, TTV has been detected by in situ hybridization in the
cytoplasm of oral epithelial cells (Rodriguez-Inigo et al., 2001), however, the meaning of
this finding is not clear. Maggi and coworkers have shown that TTV DNA loads in the
nasal cavity exceed those in the sera and thus the nasal cavity could be the primary site of
TTV infection (Maggi et al., 2003b) further supporting the droplet spread hypothesis.
Due to the history of TTV as a potential hepatitis virus, liver as a main target organ for
TTV infection has also been studied extensively. TTV is found by in situ methods in the
nucleus and/or the cytoplasm of liver cells in patients with liver damage (Cheng et al.,
2000; Jiang et al., 2000), but without any cytopathological changes (Comar et al., 2002;
Ohbayashi et al., 2001).
Replication  of  TTV in  tissues  has  been  mostly  studied  by  gel  separation,  as  well  as  with
strand-specific primer extension, and full-length PCRs. With these methods (although not
ideal for detection of replication), double-stranded, circular and potentially replicating
forms of TTV have been detected in a variety of tissues: lung, stimulated PBMC, bone
marrow cells, liver, lymph node, thyroid gland, spleen, pancreas, and kidney (Bando et al.,
2001; Mariscal et al., 2002; Okamoto et al., 2000e; Okamoto et al., 2000f; Okamoto et al.,
2001a). In Rhesus monkeys experimentally infected with TTV, the viral DNA was detected
in various organs (Luo et al., 2000), whereas replicative forms were detected only in liver,
bone marrow and the small intestine (Xiao et al., 2002).
Several viruses are known to integrate into host genomes, however, TTV seems not to
integrate, at least not in hepatocytes, PBMCs or hematopoietic tumor cells (Nishizawa et
al., 1997; Tanaka et al., 2000a; Yamamoto et al., 1998; Yu et al., 2002). In addition to the
Review of the literature
40
presence of TTV DNA in certain cell types, the enhancer activity of the TTV promoter has
been studied in various cell lines. The activity was highest in K562 human erythroleukemia
cells, and also in HepG2 human hepatocellular carcinoma cells (Kamada et al., 2004),
further supporting that these two cell types are the targets of TTV infection.
Only two in vitro studies on TTV infection in cell lines have been published. Desai and
coworkers infected with TTV genotype 1-positive pooled sera a Chang liver cell line, the B
lymphoblast cell line Raji, and stimulated PBMC. Chang liver cells produced constant, low
amounts of TTV upon cell passage, whereas in PBMC and in the Raji cell line the virus
release was transient (Desai et al., 2005). Leppik and coworkers transfected Hodgkin’s
lymphoma-derived cell line L428 with a full-length TTV clone, and demonstrated TTV
DNA recirculation and replication in the cells (Leppik et al., 2007).
The best candidates at the moment for TTV host cells are cells of hepatic and those of
erythroid origin. However, the lack of efficient virus culture systems and well-characterized
animal models, leave our current knowledge on anelloviruses’ life cycle, infection
mechanisms, and target cells/organs inadequate.
9 IMMUNOLOGY OF VIRUS INFECTIONS
9.1 Immunological battle between viruses and hosts
When a virus infects its host, specific defence mechanisms are usually initiated by the host
to clear the infection: for example plants (and higher organisms) use micro-RNAs, bacteria
use restriction enzymes and animals have an immunological system. The human immune
system is divided into innate and adaptive immunity. Innate immunity is the second-line
defence, while skin and mucosa are the first line, against invading microbes. As players of
the innate system, phagocytic cells (macrophages and neutrophils) ingest and destroy
invaders, whereas natural killer cells recognize and destroy the infected cells by sensing
viral proteins and MHC-I reduction. Complement protein C3b binds to invaders opsonising
them for phagocytes and also directly lysing enveloped viruses by activating the lysis
complex. Infected cells and cells of the innate system secrete cytokines [e.g. interferons
(INF) ,  and , and TNF- ], compounds that activate and coordinate other innate
immunity  cells  and  initiate  the  adaptive  immunity  reaction.  In  addition,  IFNs-  and  
produced by infected cells, induce the cells to die, and predispose the neighbouring cells
also to die upon infection. Complement-coated viruses are efficiently targeted to B cells
and follicular dendritic cells, and large natural IgM/antigen complexes are efficiently
filtered by the spleen, thus increasing the concentration of the antigen in lymphoid organs,
thereby linking innate and adaptive immunity (Flint et al., 2004; Hilleman, 2004;
Ochsenbein et al., 2000; Zinkernagel, 1996).
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The cytokines produced by the cells of the innate system activate dendritic cells in tissues.
Dendritic cells engulf viruses, migrate to lymph nodes and present antigens to helper T
cells, and thus activate the adaptive immune system. The helper T cells orchestrate the
adaptive immunity by activating antigen-specific B cells, and by involvement in activation
of cytotoxic T cells. The activated B cells mature into plasma cells that produce large
amounts of antibodies (IgM, IgG and IgA), and also form memory B cells. Activated
cytotoxic T cells migrate to the infected tissue and destroy infected cells. The cell-free
virions are bound by antibodies which block the infectivity of viruses and/or opsonise them
to be engulfed by phagocytes. In addition, antibodies also promote cellular cytotoxicity.
The two branches of the immune system interact: the innate immune system signals to the
adaptive immunity system which agent has invaded the body. Innate immunity is fast, non-
specific (recognizes patterns) and has no memory, while adaptive immunity is slow,
specific (recognizes specific antigens), and can protect against re-infection. The adaptive
immunity can not be fully launched unless the innate immunity is triggered by the invader
(Flint et al., 2004; Hilleman, 2004; Ochsenbein et al., 2000; Zinkernagel, 1996).
Viruses have generated numerous ways to overcome the immune responses in order to
survive within the host. Large viruses have several genes encoding proteins for these
purposes. Viruses try to avoid innate immunity by releasing progeny virions by budding
(i.e. without cell lysis), keeping dsRNA levels low or absent (i.e. no cytokine production
from infected cells), and by producing proteins that interfere with interferon responses.
Furthermore, viruses can block the effects of cytokines by interfering with cytokine or
receptor production, and with their functions. Viruses can mislead NK cells by expressing
MHC protein analogs on the surface of the infected cells. Adaptive immunity is fought by
the production of a large number of defective virions that exhaust virus-specific antibodies,
by reduction of MHC-I expression (i.e. less cytotoxic T-cell activity), and by mutations (i.e.
antibodies do not recognize the mutated protein). Viruses can further evade immune
responses by producing proteins that restrict, modify, redirect or ablate the expression or
function of cells of the host immune system. Proteins can also act as ligands or receptors
that antagonize/agonize host cell functions in favor of the virus. In addition, a high
mutation rate, especially among RNA viruses, and antigenic shift and drift help to escape
the immune control. In persistent infections, viruses can infect non-permissive or semi-
permissive cells, remaining latent and non-replicating, and thus avoiding cell destruction.
The virus may also be stored in various body compartments that immunological responses
do not reach, for example in the brain. Viruses have also developed several ways to prevent
cells from presenting antigens. The cell cycle and apoptosis are also controlled in various
ways, and several mechanisms are used to evade antibody and complement actions.
Moreover, some viruses, like Aleutian mink disease virus of the family Parvoviridae (Best
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et al., 2005), even take advantage of antibodies in order to infect their target cells;
antibody-dependent enhancement of infection (Hilleman, 2004; Ochsenbein et al., 2000;
Takada et al., 2003; Zinkernagel, 1996).
9.2 Immunology of TTV infections
TTV, harboring a small genome, has restricted capacity to encode proteins for immune
evasion. For TTV the studies on this topic are limited. Antibodies against TTV have been
determined with various methods. Tsuda and coworkers mixed patient serum with fecal-
derived TTV, followed by immunoprecipitation. TTV PCR was performed on the
supernatant and from the pellet: a higher intensity of PCR-amplicon signal from the pellet
than from the supernatant represented immunoprecipitation of TTV particles, and thus the
presence of TTV-specific antibodies in the serum. With this crude method the presence of
IgG antibodies in patients with and without TTV DNA, as well as after clearance of TTV
DNA, was demonstrated (Tsuda et al., 1999). For detection of IgM antibodies a method
using IgM capture, followed by incubation with TTV genotype-1 positive serum, was
developed. The IgM-bound TTVs were detected by PCR. With this method, IgM antibodies
for TTV were not detected in TTV DNA-negative healthy individuals, but were found in
patients with hemophilia or with HCV infection. In three patients, it was shown that after
TTV-DNA clearance, short-lived IgM antibodies appeared, followed by long-lasting IgG
antibodies (detected by the immunoprecipitation method) (Tsuda et al., 2001). Both of the
above studies were carried out on TTV genotype-1, however, it is not yet known whether
the TTV genotypes also represent serotypes, i.e. whether the antibodies cross-react between
genotypes.
Two research groups have reported the expression of the putative capsid protein, ORF1, in
two parts: the N-terminus (amino acids 1-411) (Handa et al., 2000) and the C-terminus
(amino acids 504-752) (Ott et al., 2000). Both proteins were expressed as His-tagged in E.
coli, and used as antigens in immunoblots for detection of TTV-specific antibodies. Handa
and coworkers detected antibodies against the N-terminus in 38% of US blood donors. The
majority  of  the  antibody-positives  were  also  TTV-DNA  positive  (one  for  the  same
genotype as the protein), indicating that the antibodies could be non-neutralizing and non-
protective against re-infection (Handa et al., 2000). Ott and coworkers detected TTV-
specific antibodies (IgG+IgA+IgM) in 98.6% of the tested sera, and TTV DNA in 76.1%.
When IgM was tested alone, no responses were detected (Ott et al., 2000). In addition, one
group has reported the expression of the N22 region within ORF1 (120 amino acids) but
found no antibodies in immunoblotting (Lo et al., 1999) suggesting that the area expressed
was non-immunogenic (or was not immunogenic under denaturating conditions).
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TTV particles can form immunecomplexes in the sera of infected subjects (Itoh et al., 2000;
Maggi et al., 2006; Tsuda et al., 1999), and over 90% of the virions are cleared every day
(Maggi et al., 2001c). Interestingly, it has been suggested that TTVs are immunecomplexed
in persistent infection, but not in acute infections (Nishizawa et al., 1999). Super-infection
with a new genotype was shown to result in an increase of viral load, and in a reduction of
immunecomplexed virions. After the super-infecting genotype was resolved, the
immunecomplexes and viral loads reverted. It is puzzling why the underlying genotypes
were not resolved, however, as suggested by the authors, one explanation could be that the
preformed antibodies are more effective in clearing acute than established infection (Maggi
et al., 2006).
It has been shown that the viral loads and/or TTV DNA prevalence increase in
immunosuppressed subjects, such as transplant recipients (Moen et al., 2003) and HIV-
infected patients (Sagir et al., 2005a; Touinssi et al., 2001). Higher TTV levels have been
observed in patients with lower CD4+ cell  counts  (Christensen  et  al.,  2000;  Sagir  et  al.,
2005b; Thom et al., 2007), suggesting that the viral load could reflect the patient’s immune
status (Madsen et al., 2002; Sagir et al., 2005a; Shibayama et al., 2001). On the other hand,
TTV viremia does not appear to correlate with a decreased CD4+ cell count, suggesting that
HIV-related immunedeficiency alone is not a sufficient cause for elevated TTV or TTMV
viremia.  In  addition,  results  indicating  that  HAART  (highly  active  antiretroviral  therapy)
reduces TTV levels even without increase in CD4+ cell count, suggest that some
immunological mechanism other than CD4+ cell-related acts in reduction of TTV viremia
(Madsen et al., 2002; Moen et al., 2002c).
Interferons, the mediators of the immune system, are widely used for the treatment of
chronic hepatitis B and C virus infections. The effect of interferons has been studied also in
TTV infections. Several studies have shown TTV and TTMV levels to decrease during
treatment, but no permanent outcome was achieved. This indicated suppression of TTV
replication but not eradication of the virus (Akahane et al., 1999; Ali et al., 2002; Chayama
et al., 1999; Kao et al., 2003; Maggi et al., 2001c; Tokita et al., 2001; Umemura et al.,
2002a; Watanabe et al., 2000). Whether this re-occurence is due to re-infection or re-
activation of TTV is not known. Moen and coworkers have shown that in the interferon-
treated patients the TTV and TTMV viruses re-appeared with the same viral sequences
dominating,  thus  supporting  the  view  of  a  re-activation.  In  one  patient  they  observed
appearance of a novel strain, indicating re-infection (Moen et al., 2003). It has also been
suggested that some genotypes could be more resistant than others to interferon treatment
(Chayama et al., 1999), but these results have not been fully supported (Watanabe et al.,
2000).
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In order to establish persistent infections, like anelloviruses do, the virus must somehow
evade the immune response. It has been speculated that the HVRs of ORF1, the putative
capsid protein, are frequently mutated due to immune pressure (Jelcic et al., 2004;
Umemura et al., 2002b) and that TTV could escape immune surveillance by circulating as
quasispecies (Nishizawa et al., 1999; Umemura et al., 2002b). However, there are also
publications indicating that HVRs do not mutate during follow up (Ukita et al., 2000).
Interestingly, it has been suggested that in chronic and persistent TTV infection, the HVRs
mutate and quasispecies exist, while in acute and in resolving TTV infection, the HVRs
remain stable (Nishizawa et al., 1999).
Since animal circoviruses exert immunomodulation in their hosts, similar
immunomodulatory effects of TTV infection have been searched for. It seems that TTV
infection in hemodialysis patients has no effect on the activation or distribution of
lymphocytes (Fodor et al., 2002). However, in children with acute respiratory disease, the
TTV loads showed a correlation with the B-cell percentage, and an inverse correlation with
the T cell percentage, possibly suggesting that TTV replication could cause lymphocyte
imbalance and be immunosuppressive (Maggi et al., 2003c). It is not known what the
mechanism and consequences of this phenomenon are; neither is it known are the viral
loads a cause or an outcome of lymphocyte imbalance. A recent publication by Zheng and
coworkers showed - intriguingly - that the ORF2 protein could suppress the NF- B activity
and thereby inhibit transcription of downstream genes involved in virus-related
inflammations. This could be one mechanism for TTV to modulate the immune response
and to establish persistent infection (Zheng et al., 2007).
How TTV can subvert the antibody responses and why the antibodies produced are not able
to eradicate the virus, is a mystery. In addition, the entire field of TTV-specific T-cell
immunity in healthy individuals remains to be explored.
10 DISEASE ASSOCIATIONS
Viruses can cause diseases by a number of different mechanisms. Replication may lead to
cell lysis upon release of progeny virions, viral infection may induce the cell to kill itself
(apoptosis), the immune reaction may eliminate the infected cells, or may lead to
immunopathogenic events, or viral infection may cause uncontrolled cell proliferation.
Also infection of an unnatural host can lead to disease, e.g. tick-borne encephalitis virus
(TBE) causes no disease in rodents but encephalitis in humans.
Approximately 800 articles have been published on anelloviruses (January 2008;
www.pubmed.gov), of which the majority attempt to link anelloviruses with various
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diseases. Since the outcome of a given study is highly dependent on the PCR method used,
considerable discrepancies have arisen. Taken together; it is possible that some
isolates/genotypes could cause some diseases, either alone or co-infecting with other TTV
strains or other pathogens. It is likewise possible that TTVs per se do not cause any disease,
but that they somehow have an effect on the outcome or the progression of some disease(s)
(either good or bad). Also the levels of TTV in tissue and/or in blood could affect any of
the conditions mentioned above. And finally, it is possible that TTV does not have any
effect on our well-being. Taking into consideration the wide array of different
isolates/genotypes, and bearing in mind that the only methods in current use for detection
of TTV infections (only acute and persisting, not past infections) are PCR-based, it is
obvious that the results on disease associations of TTVs are inconsistent. Two excellent
review articles exist on this (Bendinelli et al., 2001; Hino et al., 2007), in addition to two
noteworthy editorials (Naoumov, 2000; Simmonds, 2002), and the following section
simplifies and briefly summarizes what has been studied and found.
10.1 Diseases potentially related to TTV infection
Liver diseases: Due to the discovery of TTV from a patient with hepatitis (Nishizawa et al.,
1997), many studies have addressed the connection (if any) between TTV and hepatic
disorders including non-A to -E viral hepatitis, transfusion associated hepatitis, cryptogenic
chronic liver disease, liver chirrosis, hepatitis-associated aplastic anemia, fulminant
hepatitis, hepatocellular carcinoma and alcohol related liver diseases.
The  initial  studies  did  show  an  association  between  TTV  prevalence  and/or  loads  and
various hepatic disorders (Charlton et al., 1998; Ikeda et al., 1999; Kanda et al., 1999;
Nishizawa et al., 1997; Okamura et al., 2000; Tanaka et al., 1998a). It has also been
suggested that persistent TTV infections in the patients could contribute to hepatic failure
(Takayama et al., 1999a). However, contradictory results were presented indicating that
TTV  is  not  associated  with  ALT  levels  or  with  hepatic  disorders  (Hijikata  et  al.,  1999a;
Hsieh et al., 1999; Nakano et al., 1999; Naoumov et al., 1998; Niel et al., 1999; Prati et al.,
1999; Viazov et al., 1998b; Yamamoto et al., 1998). It has been noted that the levels of
TTV viremia can be higher in patients with hepatitis, which, in consideration of
methodological sensitivity, could be interpreted as a “higher prevalence” of TTV in those
patients (Pistello et al., 2001). Whether TTV replication would be a cause or a consequence
of the liver damage is not clear (Nobili et al., 2005).
According to one hypothesis certain genotypes/genogroups could be associated with
hepatic disorders (Okamura et al., 2000; Tokita et al., 2001; Tuveri et al., 2000). Especially
SENV isolates have been extensively studied in this regard. Even though, based on some
studies, the SENV-D and SENV-H isolates are more common in patients with hepatitis (He
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et  al.,  2003;  Umemura  et  al.,  2001b),  it  seems that  infection  is  not  related  to  hepatitis  or
other liver diseases (Akiba et al., 2005; Kao et al., 2002; Momosaki et al., 2005; Schröter et
al., 2003; Shibata et al., 2001; Umemura et al., 2001a; Yoshida et al., 2002).
Co-infections  of  TTV  with  other  hepatitis  viruses  (mainly  HBV  and  HCV)  have  been
widely studied. Although high TTV loads have been associated with the occurrence of
hepatocellular carcinoma in patients with HCV-related chronic liver disease, it is not clear
if TTV is a cause, a co-factor or a marker of the disease (Tokita et al., 2002). In any case,
based on several studies, co-infections with TTV seem not to have any effect on the
severity of hepatitis or other hepatic disorders due to HBV or HCV (Campo et al., 2000; He
et al., 2003; Hsu et al., 2003; Kato et al., 2000; Schröter et al., 2003; Tuveri et al., 2000;
Umemura et al., 2001a).
In summary, TTV does not fulfill the criteria for being a hepatitis virus: it does not appear
to cause any damage to the liver cells (Shimizu et al., 2000), transmission to chimpanzees
does not cause elevated ALT levels or hepatitis (Mushahwar et al., 2001), and according to
several reports in addition to those cited, no statistically important difference in comparison
to controls exists in TTV prevalence, loads, sequence variation, genotype distribution, or
co-infection among liver disease patients (Ali et al., 2002; Azzi et al., 2001; Chan et al.,
2001a; Erensoy et al., 2002; Hsu et al., 2003; Huang et al., 2000; Ikeuchi et al., 2001; Kato
et al., 2000; Kurihara et al., 2001; Masia et al., 2001; Mikuni et al., 2002; Nishiguchi et al.,
2000; Tanaka et al., 1999; Watanabe et al., 2000; Wong et al., 2002).
Respiratory tract disorders: TTV infection has been suggested to have a role (either active
or opportunistic) in children with acute respiratory disease. TTV has been found in higher
loads in nasal swabs especially in patients with a more severe respiratory tract disease, like
bronchopneumonia  (Maggi  et  al.,  2003b).  Also  the  prevalence  of  SAV  was  higher  in
children with acute respiratory syndrome (Chung et al., 2007). In addition, children with
high TTV loads in nasal specimens were shown to have worse spirometric values, and TTV
was suggested to contribute to the pathogenesis of asthma. It was suggested that TTV
replication could twist the immunobalance towards the Th2 response that is known to have
a role in the pathogenesis of asthma (Pifferi et al., 2005). In idiopathic pulmonary fibrosis
patients a poorer survival rate was suggested to correlate with TTV infection. Interestingly,
TTV replication has been shown to occur in lung tissue (Bando et al., 2001). Furthermore,
high TTV loads were associated with severity of bronchiectasis (Pifferi et al., 2006).
However, as with all the other disorders mentioned, it is not known if TTV is the cause or
the result of (or a bystander in) the disease. In one study, a newborn and the parents were
followed for TTV loads in saliva. The newborn acquired a TTV strain from the mother
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within a few days after delivery, and showed high viral loads in saliva associated with
benign rhinitis (Biagini et al., 2003).
Co-infections with other pathogens:  Co-infection  of  cervical  cells  with  TTV  and  human
papillomavirus (HPV) has been shown to occur. Even though women with multiple HPV
infections had a higher prevalence of TTV, there was no correlation to high-risk or low-risk
HPV strains (Calcaterra et al., 2001). Higher TTV loads have been detected in gastrict
tissue of patients with gastritis and with Helicobacter pylori possibly suggesting some role
for TTV infection (Maggi et al., 2003a).
Immunocompromised patients:  It  has  been  suggested  that  some genotypes  could  be  more
common in HIV-infected patients than in healthy individuals (Shibayama et al., 2001). In
addition, TTV viral loads have been shown to increase in HIV patients who are progressing
towards AIDS, and to correlate with a low CD4+ cell count (Christensen et al., 2000; Sagir
et al., 2005a; Shibayama et al., 2001; Thom et al., 2007; Touinssi et al., 2001). However,
this most probably reflects the overall immune status of the patient and has no consequence
on the underlying disease.
Cancer: TTV DNA has been found in various lymphoma types as often as in healthy
individuals, and the virus has been shown to localize in non-neoplastic cells. However, it
was postulated that TTV could somehow modulate the T cells it infects and thus have some
role in the pathogenesis of lymphomas (Garbuglia et al., 2003). Zur Hausen and coworkers
have presented an interesting hypothesis in which they suggest that persistent TTV
infections increase the risk for specific translocations, having thus an effect on the
development of childhood leukemias and lymphomas (zur Hausen et al., 2005). Co-
infection with HPV and TTV genotype-1 have been related to poor outcome of laryngeal
carcinoma, however, it is not known if TTV has any effect on the cancer progression
(Szladek et al., 2005). TTV DNA has been detected in a wide variety of neoplastic tissues
(de Villiers et al., 2002), however, this could be due to tissue inflammation, or to the
rapidly dividing cancer cells supporting TTV replication. Presence of TTV in colorectal-
cancer specimens has been suggested to have some pathogenetic role, however, the same
TTV isolates were found also in non-cancerous tissue (de Villiers et al., 2007). TTV DNA
was detected more often in the sera of patients with classical Kaposi’s sarcoma than in sera
of healthy subjects. In addition, TTV DNA has been detected in lesional skin, as well as in
healthy skin of patients, but not in the skin of healthy individuals. It was suggested that
TTV infection could, for example by immunosuppression, have some effect on the
replication of human herpes virus 8 and thus have a role in the disease pathogenesis (Girard
et al., 2007). TTV has been shown to occur in 100 times higher loads in the PBMCs of any
cancer patient tested than in healthy controls. However, it is not clear if this is due to the
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cancer or represents something in common with the seriously ill patients (Zhong et al.,
2001b).
Autoimmune disorders: Several autoimmune disorders still lack a definitive causative
agent, and TTV has been studied in this regard as well. Gergely and coworkers noticed
peptides from ORF1 and ORF2 areas to resemble human endogenous retrovirus-encoded
nuclear protein, a common autoantibody-generating epitope of systemic lupus
erythematosus (SLE). They showed that patients, in addition to having high TTV DNA
prevalence, had antibodies against the peptides. However, it is not clear whether TTV has a
role in autoantibody generation, or whether, due to immunological-dysfunction, the patients
could be more prone to TTV infections (Gergely et al., 2005b). Sospedra and coworkers
showed that T-cells obtained from multiple sclerosis patients reacted against arginine-rich
peptides similar to the TTV and TTMV ORF1 N-terminus. It was suggested that these T-
cells could be expanded due to repeated TTV infections, and in conjunction with some
other predisposing factors (genetic/microbial) could have some effect on the development
of the disease (Sospedra et al., 2005). In addition, TTV has been found in patients with
rheumatoid arthritis (Gergely et al., 2005a; Hirata et al., 1998)and with idiopathic
inflammatory myopathy (IMM) (Gergely et al., 2005a). However, the TTV prevalence did
not differ from that of blood donors (Gergely et al., 2005a). Maggi and coworkers have
shown that rheumatoid arthritis patients, when compared to healthy subjects, did not have
elevated TTV loads, whereas patients with arthritis related to other autoimmune diseases
and SLE, did. The authors suggest that there could be a connection between TTV
replication and arthritis, but as with the other disorders mentioned, causality is not known
(Maggi et al., 2007).
Interestingly, the expression of genotype-1 ORF1 in transgenic mice, leading to production
of  a  spliced  protein,  caused  pathological  changes  in  the  kidneys.  Expression  of  the  TTV
protein seemed to interfere with differentiation of the renal epithelial cells, the importance
of which in TTV pathology remains to be revealed (Yokoyama et al., 2002).
Although TTV is potentially related to many diseases, due to its global presence in healthy
subjects (i.e. lack of controls) and due to the lack of abnormalities in TTV-infected cells,
conflicting opinions exist on TTV’s disease-causing potential. It has been suggested that
smaller sub-genomic fragments of TTV identified in human sera could have some role in
diseases as is the case with plant geminiviruses (Leppik et al., 2007). In addition, it could
be possible that certain genotypes/genogroups could be more pathogenic than others
(Maggi et al., 2003b; Maggi et al., 2007), as seen for example with human papillomavirus.
On the other hand, before anything definitive can be said about the pathogenicity of TTV, it
must be noted that TTV replicates in PBMC that are frequently found in infected or
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destructed tissues. Thus, the presence or variation of loads of TTV DNA in tissue samples
that contain PBMCs may not be direct causal evidence for a disease. At the site of
infection/tissue destruction, it is also possible that the TTVs in dying cells begin to replicate
in order to rescue themselves. Thereby it is possible that the TTV loads in patients can be
higher as a secondary phenomenon, giving thus a statistical relationship without a causal
relationship with the disease (Biagini et al., 2006b). Vaccination with a new antigen seems
to boost TTV replication, suggesting that TTV loads could be increased due to co-infection
with other pathogens (Maggi et al., 2005b). TTV infections with multiple genotypes, as
well as low and fluctuating levels of viremia, make the discovery of potential disease
associations with the currently existing methods extremely difficult. PCR systems for
detecting, differentiating, and quantifying all the genotypes and/or genogroups should be
set up, as should methods to detect past infections and immunological responses to
anellovirus infections.
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AIMS OF THE STUDY
In 1998 when this study began, no information existed on the worldwide prevalence, cell
biology, or the immunology of the newly detected virus, TTV. We wanted to answer these
questions by setting these aims for our study:
To reveal the prevalence of acute, past and persistent TTV infections in the Finnish
population
To clone (at least) one genotype in full length for cell biological studies
To analyze the genome, transcription, proteins and replication of TTV
To  find  the  host  cells  for  cell-biological  research  and  for  growth  of  the  virus  for
diagnostic purposes
To express all TTV proteins
To reveal the immunology in TTV infections by studying B- and T-cell responses
To set up diagnostic tests for TTV infections (DNA and antibody based tests)
To seek possible disease associations
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SUMMARY OF MATERIALS AND METHODS
This section briefly summarizes the materials and methods used in this thesis work. More
detailed descriptions are found in the original publications (I-V). The nucleotide numbering
in this thesis is according to the GenBank submission AY666122 (supplement 1).
Northern blot analyses, RNase protection assays, mRNA 3’- and 5’-end sequencing, 9-
amino-acid hemagglutinin (HA)- and green fluorescent protein (GFP)-tagging of the
proteins, Western blotting with -HA antibody, confocal microscopy, and Southern
analysis with radioactive probe were done by the collaborators, and are explained in detail
in the original publications (III, IV).
1 SAMPLES
1.1 Patient samples (I, II, V)
Serum samples for study I were obtained from 89 non-symptomatic adults (80 of those
were Finnish), of which 25 were used in study V. For study II, plasma, peripheral blood
mononuclear cells (PBMC) and bile samples were obtained from 31 Finnish patients during
abdominal operations in conjunction with cholecystectomy. Liver, plasma and PBMC
samples were obtained from 3 Finnish patients with ulcerative colitis. Liver DNA
preparations were obtained from 17 B19 DNA positive German patients. Skin, synovial and
serum samples were obtained from 13 Finnish patients, synovial tissue from joint trauma
patients. Adenoidal and tonsillar tissue samples were obtained from 6 patients with
adenoidectomy and 10 with tonsillectomy for hyperplasia or chronic infection. More
detailed descriptions of the patients are found in the original publications (I, II, V). Samples
were collected from the patients with informed consent. The studies involving patient
material were approved by The Ethical Review Committee of the Helsinki University
Central Hospital.
1.2 Processing of the samples (I, II, V)
Sera were collected from coagulated blood. Bile samples were centrifuged for 2 minutes
before  DNA  isolation  from  the  supernatant.  Plasma  and  PBMC  were  separated  with
Vacutainer Cell Preparation Tubes (Becton Dickinson), and the cells possibly remaining
were  removed  from  plasma  by  centrifugation,  and  PBMC  were  washed  three  times  with
PBS followed by re-suspension into PBS. All the samples were stored at -20 C until DNA
isolation.
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1.3 DNA isolation from clinical material and cultured cells (I, II, IV, V)
The  total  DNA  for  PCR  studies  (I,  II,  V)  was  isolated  from  the  patient  samples  with
proteinase-K treatment and phenol-chloroform extraction, was precipitated with Na-acetate
and ethanol, and was re-suspended into water (except in study II the 17 German liver
samples, see reference therein). The total DNA for Southern analyses (IV) was isolated
from  the  transfected  cells  with  phenol-chloroform  method,  or  with  QIAamp  DNA  Blood
Mini Kit (Qiagen). The low molecular weight DNA was also isolated with the Hirt protocol
(Hirt, 1967).
2 PCR
2.1 TTV PCRs and B19 PCRs (I, II, IV, V)
Universal-PCR (UTR-PCR) (I,  II,  IV,  V):  The  highly  conserved  area  of  TTV,  the
untranslated region (UTR), was amplified (nt 88-230) by nested-PCR with the primers
NG133, NG147, NG134 and NG132 (Table 1) (Okamoto et al., 1999b). PCR mixtures
contained 200 M each dNTP, 600 nm each primer, 1.5 mM MgCl2, and 2.5 U AmpliTaq
Gold polymerase. Amplification conditions for 35 cycles were as described by Okamoto
and coworkers. Briefly, annealing was at 60 C, and elongation was for 40 seconds
(Okamoto et al., 1999b).
N22-PCR (I): The N22 region within the ORF1 coding area was amplified (nt 1840-2169)
by nested-PCR with the primers TT6, TT7, TT8 and TT9 (Table 1) (Höhne et al., 1998).
PCR conditions were as in UTR-PCR, except that the annealing was at 42 C, and
elongation was for 45 seconds.
Genotype-6 PCR (I, II, IV, V): The nested PCR, overlapping the N22 region, was designed
(nt 1803-2200) to amplify HEL32-like sequences. The primer sequences are in the Table 1.
Amplification conditions were as with UTR-PCR, except that the annealing was at 55 C for
the outer PCR and at 52 C for the inner PCR.
B19 PCR (II): The nested-PCR for human parvovirus B19 (nt 2407-2797) was done with
primers p6f, p3r, p8f and p5f (Söderlund et al., 1997).
The  semi-quantification  of  the  DNA  amount  was  done  by  serial  ten-fold  dilutions  of  the
DNA for the PCRs.
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3 CLONING
3.1 Cloning of the PCR products (I, V)
The amplicons were isolated from PCR mixtures or from agarose gels, and cloned into the
pSTBlue-1 AccepTor vector in Escherichia coli DH5  (I).
3.2 Construction of the full-length TTV plasmid clone (I, IV)
The 3381-bp region of the HEL32 isolate was amplified by PCR from the serum of a
Finnish non-symptomatic female, and cloned in two overlapping pieces into the pSTBlue-1
AccepTor vector. A 3269-bp product (nt 111-3380) was amplified with nested-PCR using
primers NG133, NG135, NG134 and NG136 (Table 1) (Okamoto et al., 1999b). The PCR
reactions contained 200 M dNTP, 320 nM primers, 1.5 mM MgCl2, and 2.6 U of Expand
High Fidelity enzyme mix (Boehringer Mannheim/Roche). The PCR programs consisted of
annealing at 54 C and extension at 68 C  for  2.5  min  for  the  first  10  cycles,  with  5
seconds/cycle added during each of the last 20 cycles. The PCR product was isolated from
agarose gel, and cloned for sequencing into the pSTBlue-1 AccepTor vector in E. coli
DH5 . The region of (-)1-220 nucleotides of HEL32 was amplified with semi-nested PCR
using primers NG054, NG147 and NG132 (Table 1) (Okamoto et al., 1999b). The PCR
program was  that  of  UTR-PCR,  except  that  annealing  was  at  50 C,  extension  was  for  45
seconds and the cycles were repeated 30 times. The resulting 222-bp product was isolated
and cloned for sequencing as the 3269-bp product (I).
To  sequence  the  whole  genome of  the  HEL32,  and  to  clone  the  complete  genome into  a
plasmid, the GC-rich region (nt 3206-216) was amplified from the original serum with
semi-nested primers TTVGCF, TTVGCR1 and TTVGCR3 (Table 1). PCR reactions
contained 200 M dNTP, 400 nM primers, 1.5 mM MgCl2, 10% dimethylsulfoxide, 1 M
betaine and 17.5 U of Expand High Fidelity enzyme mix. PCR programs consisted of
annealing at 55 C  and  extension  at  72 C  for  2  min  for  the  first  10  cycles,  with  5
seconds/cycle added during each of the last 20 cycles. The resulting 759 bp amplicon was
isolated and cloned for sequencing as the 3269 bp product. For cloning of the entire HEL32
isolate a 396 bp product [nt (-)1-394] was amplified from the original serum with primers
NG054 (Okamoto et al., 1999b) and TTVGCR6 (Table 1). With restriction enzyme
digestions followed by ligations the three overlapping genomic parts were combined into
pSTBlue-1 AccepTor vector that then contained the entire genome of the HEL32 isolate
(named as pTTV), flanked by 175 bp areas.
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3.3 Sequence analyses (I, IV, V)
Sequencing of the purified PCR amplicons and of the cloned constructs (cloned PCR
amplicons,  ORFs  and  TTV  clone)  was  done  at  the  sequencing  core  facility  of  Haartman
Institute at University of Helsinki, Finland (I, IV).  Sequencing of the cloned GC-rich
region of HEL32 was done at the DNA sequencing facility of the Institute of
Biotechnology at the University of Helsinki, Finland (IV).
For  database  searches  the  program Blast  was  used  (NCBI)  (I).  For  genomic  organization
analyses programs MapDraw (DNAStar) and DNAStrider were used (I). Multiple sequence
alignments and evolutionary distance analyses were done with Pileup, GrowTree and
Distance programs (I). Phylogenetic trees were constructed with the program TreePuzzle
using the maximum likelihood approach, with 10 000 puzzling steps using the HKY model
of substitution, and with the program Phylip using the neighbour-joining algorithm with
500 bootstrap replicates (references for these are found in the original publication I).
4 CELLS AND TRANSFECTIONS
4.1 Cell lines and cell culture (III, IV)
Altogether seven cell lines were used in these studies: Cos-1, Huh7, Chang liver,
KU812Ep6, UT/Epo-S1, 293T and 293. Cos-1 cells (African green monkey kidney cells,
transformed with SV40) were maintained in D-MEM with 10 mM HEPES Buffer, Huh7
cells (human hepatoma cell line) and Chang liver (human liver cell line) in MEM, and 293
cells (human kidney derived cell line) and 293T cells (expressing SV40 T antigen) in D-
MEM. KU812Ep6 cells (human erythroid leukaemia cell line) (Miyagawa et al., 1999)
were maintained in RPMI1640 with 6 U/ml of erythropoietin (Janssen-Cilag) and
UT7/Epo-S1 cells (human erythroblastoid cell line) (Morita et al., 2001; Shimomura et al.,
1992) were maintained in Iscove’s modified Dulbecco’s medium with 2 U/ml of
erythropoietin. All cell lines were grown in the presence of 10% FBS and antibiotics, and at
37 C in 5% CO2. Cells were monitored for the presence of TTV DNA by UTR-PCR and by
genotype-6 PCR.
4.2 Aphidicolin treatment (IV)
For aphidicolin treatment of 293T cells, 2 g/ml of aphidicolin (Sigma) was added to the
growth medium. The cells were transfected in the presence (calcium phosphate), or in the
absence (lipofection) of aphidicolin, and grown further in the presence of aphidicolin. The
non-treated 293T cells were included as controls (IV).
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4.3 Transfection (III, IV)
The adherent cells (Cos-1, Huh7, Chang liver, 293T and 293) were transfected with 5 g of
DNA per 60 mm2 plate at approximately 95% confluence on day 1 post subculture. For
lipofection, the amount of Lipofectamine2000-reagent was optimized for each cell line (the
amounts used are found in publication IV). 293 and 293T cells were also transfected by the
calcium phosphate technique.
Cells growing in suspension were transfected at the exponential growth phase (days 3-4
post subculture). For KU812Ep6 cells the conditions of electroporation were optimized;
2x106 cells were transfected with 5 g of DNA by electroporation at 300 or 350 V, and 960
F.  For  transfection  of  UT7/Epo-S1 cells  the  Amaxa Nucleofector  system was  used  with
Kit R and program T-24 (Amaxa Biosystems).
For study III, the localization of the GFP-constructs was analyzed in transfected 293T and
HuH7  cells.  For  study  IV,  the  pTTV  was  constructed  so  that  the  complete  genome  with
overlaps was inserted between EcoRI sites in the pSTBlue-1 AccepTor vector, and that
BspEI could be used to excise in a single unit the complete TTV genome (without overlaps)
in linear form. The cells were transfected with two forms of cloned TTV genome: an uncut
plasmid clone, pTTV, containing overlaps, and a linear construct, linTTV (full-length
genome without overlaps, excised with BspEI).
The transfection efficacy in each experiment was optimized and observed with the pEGFP-
Luc vector encoding the green fluorescent protein (GFP), and the percentage of transfected
cells was estimated with a fluorescence microscopy on day 1 post transfection (III, IV).
4.4 Microscopy (III, IV)
The GFP signal in the transfected cells was observed with fluorescence microscopy (III,
IV).
5 HYBRIDIZATION-BASED ANALYSES
5.1 Dot blot assay (I)
The products of UTR-PCR were confirmed by a dot-blot assay. The probe for hybridization
was prepared by PCR from the cloned HEL32 isolate. The probe was labelled with the
inner UTR-PCR by incorporating digoxigenin-11 dUTP. The products of genotype-6 PCR
were confirmed also by the dot-blot assay. The probe was prepared similarly to the
previous probe, but with the inner genotype-6 PCR.
Summary of materials and methods
56
5.2 Southern hybridization (IV, V)
For replication assays the total DNA isolated from the transfected cells was digested with
BamHI and DpnI, separated by gel electrophoresis and transferred to a nylon membrane
(Hybond-N+, Amersham Biosciences). The membranes were hybridized with a DIG-
labelled PCR-probe covering nucleotides 1803-2200 (prepared with the outer genotype-6
PCR) (IV). For replication assays with radioactive label, the 32P-labelled probe was
prepared to cover nucleotides 2788-3348 (560 bp) of the untranslated region (IV).
For circularization experiments total isolated DNA was digested with various enzymes,
separated by gel electrophoresis and transferred to the nylon membrane. The membranes
were hybridized with a DIG-labelled probe prepared by nick translation using DIG-Nick
Translation Mix (Roche) to cover the entire TTV genome (IV).
To confirm the genotype-6 PCR and dilution series results, the obtained amplicons in the
gels were transferred to the nylon membrane and were hybridized with the genotype-6 PCR
generated probe (V).
For the hybridization procedures involving a DIG label, the membranes were hybridized at
42 C overnight. The DIG label was detected with 5-bromo-4-chloro-3-indolyl-phosphate
(BCIP) and 4-nitro blue tetrazolium chloride (NBT) forming a coloured precipitate (I, IV).
For the hybridization procedures involving a 32P-label, the signal from the hybridized probe
was detected by film exposure (IV).
6 RNA WORK
6.1 RNA isolation and RT-PCR (IV)
The cells for RNA analyses were collected post transfection and total RNA was isolated
with TRIzol Reagent (Invitrogen Life Technologies). When necessary, residual DNA was
removed with DNases. For RT-PCR, primers RT1F and RT1R (Table 1) were designed to
flank the common 101 bp spliced intron (Qiu et al., 2005). This separated the amplicons
originating from DNA and RNA by size. RT-PCRs were done with RobusT II RT-PCR Kit
(Finnzymes) in the presence of an RNase inhibitor. The PCR program consisted of reverse
transcription at 42 C for 30 minutes, followed by 35 cycles of PCR with annealing at 65 C
and elongation at 68 C for 45 seconds. RT-PCR for retinoblastoma mRNA was done with
the primers published previously (Brunstein et al., 2000).
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7 PROTEIN EXPRESSION
7.1 Cloning of ORFs for expression systems (I, V)
Cloning of ORF1, ORF2a and ORF2b (I): In-frame primers (Table 1) with restriction sites
(underlined in Table 1) were designed for each ORF. The reverse primers were located
downstream of the stop codons. ORFs were amplified from the 3269-bp HEL32 plasmid-
clone, and the agarose-purified amplicons were cloned in-frame to GST (glutathione S-
transferase) into a pGEX-4T-1 expression plasmid (Amersham Pharmacia) in E. coli
DH5 .
Cloning of all six cDNAs (V): In-frame primers (Table 1) were designed for all six ORFs or
cDNAs. Those were amplified either with PCR from the existing clones, or with RT-PCR
from the RNA isolated from pTTV-transfected cells. For PCR amplification either Ampli
Taq  Gold  or  Expand  High  Fidelity  PCR  System,  and  for  RT-PCR  either  OneTube  Titan
RT-PCR System (Roche) or RobusT II RT-PCR Kit (Finnzymes), was used. The purified
amplicons were cloned in-frame to GST into a pGEX-4T-1 expression plasmid, and in-
frame to GST-6xHis into pAcGHLT-A Baculovirus Transfer Vector (BD Biosciences) in
E. coli DH5 .
7.2 Expression of proteins in E. coli (I, V)
Cloned ORF amplicons from pGEX-4T-1 expression plasmids were expressed as GST
fusion proteins in E. coli strain BL21 (Amersham Pharmacia). Arginine-rich proteins were
expressed  also  in  strain  Rosetta  (Novagen).  For  the  expression  of  each  construct,  growth
medium (L-Broth, YT or Terrific Broth), IPTG (isopropyl -D-1-thiogalactopyranoside)
concentration, IPTG induction time, and induction temperature were optimized.
7.3 Expression of proteins in insect cells (V)
The pAcGHLT-A Baculovirus Transfer Vectors containing the cloned cDNA constructs
were purified from bacteria with GenElute Endotoxin-free Maxiprep Plasmid Purification
Kit (Sigma), and transfected together with Linearized Baculovirus DNA (BD Biosciences)
into Spodoptera frugiperda (Sf9) insect cells. For large scale protein production, the
recombinant baculoviruses produced by Sf9 cells were used to infect either Sf9 and/or
Tricoplusia ni (HighFive) insect cells.
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8 PROTEIN AND ANTIBODY ANALYSES
8.1 SDS-PAGE and immunoblotting (I, V)
To analyze the expressed proteins, the proteins of the whole cell lysates were separated by
a 10% SDS-PAGE and the proteins were visualized by staining with Coomassie stain (I).
For  immunological  detection,  the  proteins  were  transferred  from  the  SDS-PAGE  to  a
Protran nitrocellulose membrane (Schleicher & Schuell). The membranes were blocked
with 5% fat-free milk powder and 0.2% Triton X-100 in PBS. For immunodetection,
primary  antibodies  [goat  -GST  (I),  mouse  -GST  (V),  human  sera  (I)]  and  HRP
(horseradish peroxidase)-conjugated secondary antibodies [rabbit -goat IgG (I), rabbit -
mouse IgG (V), rabbit -human IgG (I, V), rabbit -human IgM (I)] were diluted with
blocking liquid into appropriate concentrations (dilutions are in the original publications I
and V).
The bound antibodies were detected with hydrogen peroxide and DAB (3,3'-
diaminobenzidine). For IgM detection, to avoid possible interference by rheumatoid factor,
the IgG was removed from sera with Gullsorb (Meridian Diagnostics) (I).
8.2 B19 serology (II)
The second-generation epitope-type enzyme immunoassay (IgG-ETS EIA) was used for
analyzing the B19 infection status in certain patients. Briefly, acute and past B19 infections
were diagnosed by calculating the ratio of IgG binding to conformational and linear
epitopes (Kaikkonen et al., 1999).
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Table 1. Primers for TTV used in this study. Restriction sites are underlined, translation
initiation sites and stop codons are marked with capital letters. In primers used for cloning
of ORFs the numbering of nucleotides is according to those corresponding AY666122, and
thus excludes restriction enzyme sites and 5’ sequences from them.
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1 EPIDEMIOLOGY OF TORQUE TENO VIRUS
1.1 TTV DNA prevalence in sera (I, II)
In the beginning of this study, in 1998, it was not known how common TTV was in
Finland. Thus, we initiated our TTV research by testing, with two PCR methods (i.e. N22
and UTR PCRs) (Höhne et al., 1998; Okamoto et al., 1999b), the TTV-DNA prevalence in
healthy adults in the Finnish population. By the UTR-PCR (amplifying the majority of
TTV genotypes) 74/87 (85%) of the subjects were TTV-DNA positive, and additionally,
two subjects became TTV DNA positive during the follow-up. By the N22 PCR
(amplifying genotypes 1-6), 14/80 (18%) of the subjects were TTV DNA positive. Our
results were in accordance with the results presented concurrently by Simmonds and
coworkers, showing a 73% DNA prevalence among Finnish blood donors (Simmonds et
al., 1999), and in line with others showing high TTV DNA prevalences all over the world.
In our subsequent studies we focused especially on TTV of genotype 6. By genotype-
specific PCR we observed genotype-6 DNA prevalence in sera/plasma of the subjects
studied to be in the order of 4% (2/47) – 8.6% (3/35). In the literature the first reference to
genotype 6 is from Tanaka and coworkers identifying genotype-6 DNA in serum from a
Japanese patient (Tanaka et al., 1998b). Subsequently, genotype-6 isolates have also been
detected in nasal and blood samples in an Italian study (Maggi et al., 2003b), in saliva and
PBMC of Chinese patients (Chan et al., 2001a), in serum of a Japanese hemophiliac
(Takayama et al., 1999b), in serum of a Hungarian hepatitis patient (Takacs et al., 2003),
and in serum of a chimpanzee that was used in hepatitis research (Verschoor et al., 1999).
In addition, genotype 6 has been shown to establish persistent infection in PBMC and
persistent viremia in plasma (Maggi et al., 2006).
1.2 TTV DNA and genotype-6 DNA in human tissues (II)
To analyze the tissue prevalence of TTV DNA and genotype-6 DNA, we studied various
tissue  samples  with  TTV-specific  PCRs.  The  prevalence  of  another  ssDNA virus,  human
parvovirus B19, was included as a reference. Table 2 shows the results of viral DNA
prevalences in various tissues.
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Table 2. TTV DNA, genotype-6 DNA and human parvovirus B19 DNA prevalences in
tissues of various patients (more detailed descriptions of the patients are in publications I,
II, V).
TTV Genotype 6 B19 Relative titersof TTV DNA
Finnish surgical patients
Bile 24/31 (77%) 1/31 (3.%) 0/31 (0%) 100-10-3
PBMC 28/31 (90%) 0/31 (0%) NT* 100-10-4
Plasma 29/31 (94%) 1/31 (3%) NT 100-10-3
Liver samples from Finnish patients
Liver 3/3 (100%) NT NT 101-10-4
PBMC 3/3 (100%) 0/3 (0%) NT 100-10-3
Plasma 2/367%) 0/3 (0%) NT 100-10-1
Liver samples from German patients
Liver 17/17 (100%) 1/17 6%) 15/17 (88%) 100-10-3
Skin and synovial samples from Finnish patients
Skin 5/13 (38%) 1/13 (8%) 8/13 (62%) 100-10-1
Synovia 5/13 (38%) 0/13 (0%) 6/13 (46%) 100-10-1
Serum 11/13 (85%) 1/13 (8%) NT 100-10-3
Adenoidal and tonsillar samples from Finnish patients
Adenoid 6/6 (100%) 0/6 (0%) 1/6 (17%) 100-10-5
Tonsil 10/10 (100%) 0/10 (0%) 3/10 (30%) 100-10-5
*NT = not tested
Plasma, bile and PBMC of 31 Finnish surgical patients were studied by UTR-PCR, and
TTV DNA was found simultaneously in all three sample types in 24/31 (77%) of the
subjects. The remaining seven patients had no detectable TTV DNA in bile, yet three were
positive in plasma and in PBMC, two in plasma, one in PBMC, and one was negative for
TTV DNA in all three sample types. Genotype-6 DNA was detected in one patient, both in
bile and in plasma, but not in PBMC. All the bile samples were negative for our reference
virus B19 DNA, while 45% of the patients were seropositive for IgG against B19. Liver
samples from 3 Finnish and 17 German patients were all found to be TTV DNA positive.
One German liver sample contained genotype-6 DNA. B19 DNA was found in 15/17
(88%) of German liver samples, including the genotype-6 positive one. TTV DNA was
detected in 38% of skin samples and of synovial samples. Two subjects had TTV DNA in
both skin and synovia, and six in either sample type, all of those being TTV DNA positive
also in sera. One subject had genotype-6 DNA in skin and in serum. Those that were B19
DNA positive in tissue, had past immunity to B19. TTV-DNA was found in all the




To summarize our results, we detected TTV DNA and genotype-6 DNA in a number of
different tissues. The relative viral DNA titers did not vary significantly, and there was no
tissue or symptom specificity in association with genotype-6 infection. These results, and
those of others, demonstrate that genotype 6 is spread worldwide, and can be found in
various  tissues  and/or  cell  types.  In  agreement  with  our  results,  TTV  DNA  has  been
amplified from bile, PBMC, skin and liver (Jiang et al., 2000; Okamoto et al., 1999a;
Okamura et al., 1999; Osiowy et al., 2000; Rodriguez-Inigo et al., 2000; Ukita et al., 1999;
Yamamoto et al., 1998; Yu et al., 2002), while the presence of TTV DNA in synovia,
adenoids and tonsils has not been studied by others. In fact, TTV DNA has been detected
by PCR in nearly all tissues studied. However, the occurrence of TTV DNA does not
necessarily reflect productive TTV infection in the particular tissue, but instead could either
indicate the presence of TTV in some tissue-invading cells, or silent persistence of TTV
DNA in those tissues. The latter scenario has been confirmed with human parvovirus B19,
that has been shown to persist in tissues for decades (Norja et al., 2006). The high
prevalence of TTV per se is not an uncommon phenomenon among viruses, for example,
papillomaviruses and herpesviruses are frequently found in healthy individuals. However,
TTV differs from all the other viruses known with its ability to sustain viremia, i.e. to
actively replicate and produce viruses into blood continuosly for years or decades in
healthy individuals.
2 CELL BIOLOGY OF TORQUE TENO VIRUS
In order to study the cell biology of a virus, identification of host cells sustaining viral
growth is essential. In addition, an infectious plasmid clone capable of producing viruses
and easy to manipulate would greatly assist the research. We approached the cell biology
questions in the TTV field by cloning the TTV genotype 6 for use in cell biological assays.
The research on several viruses has been greatly assisted by infectious plasmid clones. For
example the replication of CAV and PCV have been extensively studied with infectious
clones and with permissive cell lines (Claessens et al., 1991; Meehan et al., 1997; Meehan
et al., 1998; Noteborn et al., 1991). The plasmid clones are easy to grow, can be
manipulated in bacteria (e.g. mutated at specific places, genome parts changed between
isolates etc.), and can be introduced into cells of any type by transfection, thereby by-
passing the need for virus receptors. The plasmid clones can be used to study a variety of
virus functions; e.g. phosphatase functions of the CAV protein were successfully revealed
by mutating the infectious clone (Peters et al., 2005; Peters et al., 2006). In addition, with
infectious plasmid clones, progeny virions can be produced. However, even though the
plasmid clone would not be infectious, several features of the virus can still be studied, as is
shown in this thesis with a full-length clone of TTV.
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2.1 Cloning and phylogenetic analysis of the HEL32 isolate (I, IV)
To investigate the coding capacity and the cell biological issues of TTV, we amplified, with
previously published primers (Okamoto et al., 1999b), the complete coding region of a TT-
virus  from  one  TTV-DNA  positive  serum.  The  coding  region  was  amplified  in  two
overlapping PCR products (3269 bp and 222 bp) that were cloned and sequenced. The
cloned TTV was found to be 3381 bp in length, and to diverge by more than 40% from the
prototype TTV, isolate TA278 (GenBank #AB017610). When we compared the ORF1
sequence of the clone to 29 TTV isolates published (Okamoto et al., 2001a), our clone was
found to be unique. By comparison of the N22-area to the 42 TTV sequences (representing
20 genotypes) (Muljono et al., 2001), our clone was closely related to the representative of
genotype 6 (Fig. 9), of which only one sequence of 222 bp had been deposited into
GenBank (#AB017777). We named our genotype-6 isolate as HEL32 (I).
Figure 9. A phylogenetic tree based on the N22 sequence of TTV isolates. Numbers
indicate the support values. Names and genotypes of the isolates are indicated.
(Reproduced from Kakkola et al., 2002, with permission.)
Subsequently,  after  successful  amplification  of  the  GC-rich  region,  a  full-length  clone  of
the HEL32 was completed (IV). The complete genome of the HEL32 isolate was found to
be 3748 nt in length, containing the GC-rich area of 107 nucleotides; this was the first full-
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length sequence reported for genotype 6. The full-length clone of genotype 6 was
constructed in such a way that it could be used for transfection experiments in two forms:
an intact plasmid pTTV containing 175 bp overlapping areas at both ends, which would
potentially aid in the recombination rescue of the viral genome from the backbone plasmid;
and a linear BspEI-excised, genome-sized form containing the 3748 nt TTV genome (Fig.
10). A similar full-length clone, with overlapping ends, had been constructed from
genotype 1, and used successfully in the investigation of TTV RNA transcription
(Kamahora et al., 2000).
Figure 10. The full-length clone of HEL32 and the constructs used for transfection
experiments. A) The clone was constructed from three overlapping PCR products (inner
black lines). B) The excised linear construct and C) the intact plasmid construct were used
for transfection experiments. The GC-rich region is shown as striped area, the TATA-box
with  *,  poly-A  with  a  black  dot,  primers  with  arrows,  and DpnI restriction enzyme sites
with diamonds. The sites for DIG- and 32P-probes are indicated with bars. The predicted
sizes of products with BamHI and DpnI based replication analyzes are indicated (the same




2.2 Analysis of the HEL32 genome (I, IV)
The genomic organization of our genotype 6 isolate was found to be similar to that of other
TTVs: a GC-rich region in the non-coding area, and putative ORFs surrounded by a TATA-
box (ATATAA, nt 82-87) and by a poly-A sequence (ATTAAA, nt 2978-2983). Sequence
analysis of the coding area of the HEL32 isolate revealed at least three possible open
reading  frames  (ORFs).  Sequence  comparison  with  41  TTV  isolates  showed  that  in  34  a
similar genomic organization was seen as in our HEL32, i.e. ORF2 in two parts, ORF2a
and ORF2b, while seven representatives of genotype 1 had ORF2 singly. ORF2a of HEL32
was predicted to encode for 49 amino acids, and ORF2b 156 amino acids. The
uninterrupted ORF2 and the spliced ORF2b products contain the amino acid motif
WX7HX3CX1CX5H  that  is  found  in  all  TTVs  and  in  the  CAV  VP2  protein  sequence
(Hijikata et al., 1999b). We found the ORF2a to be highly conserved in all isolates
(divergence at the amino acid level to TA278 was 12%), whereas the ORF2b showed
higher divergence (>50%). All TTV genotypes, including our genotype 6, as well as
TTMVs and TTMDVs/SAVs, contain one large ORF1 encoding a protein with an arginine-
rich N-terminus. The ORF1 of our HEL32 was predicted to encode a 736 amino acids
protein, however, we found the ORF1 area among the 41 TTV isolates to vary in length,
and identified also stop codons within the ORF1. The ORF2/3 protein of our isolate had a
conserved amino acid motif, E-X8-R-X2-R-X6-P-X12-19-F-X1-L (unpublished), that is found
in the C-terminus of the same protein among other TTV isolates (Okamoto et al., 2000b;
Peng et al., 2002).
2.3 RNA transcription and DNA replication (IV)
In order to examine the cell biology of TTV infection, we used our full-length TTV clone
for  studies  of  RNA transcription  and  DNA replication.  Prior  to  the  studies,  the  cell  lines
(Cos-1, Huh7, Chang liver, KU812Ep6, UT/Epo-S1, 293T and 293) were confirmed by
PCR to be free of endogenous TTV DNA and of genotype-6 DNA.
We  detected  TTV  mRNA  production  in  all  seven  cell  lines  after  transfection  with  either
pTTV or the linear construct. TTV DNA replication, indicated by DpnI-resistant TTV
DNA forms, was shown to occur in 293T, 293, Huh7, UT/Epo-S1 and Chang liver cells
(Fig. 11). TTV DNA replication was not detected in Cos-1 or KU812Ep6 cell lines.
Interestingly, the 293T cells showed more pronounced replication than 293 cells. The 293T
cells express a large T antigen-protein of a polyomavirus, simian virus 40 (SV40). This
multifunctional protein binds to the cell-cycle control proteins pRb and p53, and inactivates
them. Subsequently, the cells enter the S-phase more readily and the SV40 genome
replication can proceed (Skern, 2006; Sullivan et al., 2002). Likewise, the replication of our
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TTV clone could have been promoted by the rapidly dividing 293T cells, which would
explain the superiority of the 293T cells over the 293 cells in the replication of TTV DNA.
Figure 11. Southern analysis of TTV replication in 293T-cells transfected with linear (lin)
and plasmid (pTTV) constructs. Replication was analyzed on days 1 and 3 post-
transfection. The arrow and the asteriks indicate DpnI-resistant and replicating TTV DNA.
Other symbols indicate the input TTV-DNA. Compare to Figure 10, which schematically
illustrates the DNA fragments obtained with the restriction enzymes used in the replication
analysis. Cells transfected with the backbone plasmid (pSTBlue-1) were included as
negative control. (Reproduced from Kakkola et al., 2007, with permission.)
Our results indicated that in the transfected cells the linear construct had circularized.
Replicated forms of the linear construct were shown to accumulate with time, however, the
DpnI-resistant DNA declined after cell passage. After transfection with pTTV, replication
of the entire plasmid in the transfected liver-, kidney- and erythroid-derived human cell
lines was observed, however, without release of the TTV genome from the backbone
plasmid.  The  replication  experiments  were  confirmed  with  two  probes  (DIG  and
radiolabelled) and with two DNA isolation methods (isolation of total DNA; and isolation
by Hirt method) in two laboratories (Helsinki, Finland; and Leiden, The Netherlands).
Although we were able to demonstrate the replication of TTV DNA in the transfected cells,
we were not able to show production of infectious progeny virions, which would be the
ultimate proof of a clone being infectious. A similar, DpnI restriction enzyme-based
method was  very  recently  used  by  Leppik  and  coworkers  to  show the  replication  of  their
full-length clone of a genogroup-5 TTV isolate in a Hodgkin’s lymphoma cell line. In
addition to DNA replication, they detected with electron microscopy virus-like particles in




With PCR-based methods, others have shown replicating TTV DNA in several tissues,
especially in PBMC, bone marrow and liver (Okamoto et al., 2000e; Okamoto et al., 2000f;
Zhong et al., 2002). Furthermore, low-level TTV production, and infectivity of TTV, was
shown in activated PBMC and in a few cell lines (Desai et al., 2005; Maggi et al., 2001b;
Mariscal et al., 2002). Desai and coworkers documented in the replication-permissive
Chang liver cells a cytopathic effect post-infection. In contrast to their results, we did not
observe any cytopathic effect in our transfected cells supporting TTV DNA replication, not
even in the Chang liver cells. Whether this is due to a potential lack of virus production is
not known. In any case, the amount of TTV released from the infected Chang cells has
been shown to be very low (Desai et al., 2005), suggesting that either the virus production
is  tightly  controlled,  or  the  Chang  liver  cells  are  not  the  optimal  host  cells  for  TTV
infection.
2.4 Dependence of TTV DNA replication on cellular polymerases (IV)
Most small DNA viruses are dependent on the host cell replication machinery for virus
replication. Thus, they either infect actively dividing cells (e.g. parvoviruses) or induce the
cells to enter S-phase, and subsequently prevent apoptosis (e.g. papillomaviruses). We
examined the host cell dependence of the replication of our full-length clone by blocking
the cellular DNA polymerase with the drug aphidicolin. In the presence of aphidicolin,
TTV  DNA  replication  did  not  occur,  indicating  that  TTV  utilizes  for  genome  replication
the cellular replication machinery. Probably, as has been shown with other circoviruses,
viral proteins are needed to interact with cellular proteins for the initiation of replication;
however, with TTV these issues remain to be resolved.
Nothing else is known about the cell biology of TTV. Furthermore, little is known of the
cell biology of animal circoviruses on the whole. PCV2 has been shown to enter the cells
via clathrin-mediated endocytosis, the infection requiring the acidic environment provided
by endosomes (Misinzo et al., 2005). This entry pathway is used for example by canine
parvovirus (Basak et al., 1992; Vihinen-Ranta et al., 1998), and could also be used by TTV.




3 TRANSCRIPTION MAP AND SUB-CELLULAR LOCALIZATION OF
TORQUE TENO VIRUS PROTEINS
3.1 Transcription map of TTV genotype 6 (III)
By sequence analysis we identified three putative ORFs in our genotype-6 clone (I),
however, the effect of splicing on the mRNAs was not yet known. With a genotype-1 full-
length clone, Kamahora and coworkers showed that TTV produces three species of mRNA
by alternative splicing (Kamahora et al., 2000). In order to study if similar splicing occurs
with our genotype, and to obtain a more detailed transcription map, our full-length clone
was transfected into 293 cells, and the produced mRNAs were analyzed.
Three species of mRNAs were identified (Fig. 12): an intron from nt 182 to nt 284 was
spliced from all of them, and by alternative splicing a second splicing joined the common
5’ splice site (2D, nt 703) to alternative 3’ splice sites (2A1, nt 2315 or 2A2, nt 2505).
Furthermore, with alternative translation initiation codon usage, altogether six putative
proteins were predicted to be translated. From the 2.8 kb mRNA the full-length ORF1 (737
aa) could be translated. Splicing in the middle of ORF1-encoding mRNA created also an
ORF cabable of encoding a shorter protein, ORF1/1 (199 aa), containing the N- and the C-
terminal parts of the ORF1-encoded protein. For translation of protein ORF1/2, alternative
splicing combined the 5’-sequence of ORF1 into a different reading frame, resulting in an
ORF cabable of encoding a protein that has an N-terminus identical to that of the ORF1-
encoded protein but with a C-terminus encoded in another reading frame.
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Figure 12. The transcription and translation map of TTV isolate HEL32. Translation
initiation sites, splice junctions and poly-A sites are indicated with numbers. (Reproduced
from Qiu et al., 2005, with permission.)
The ORF2-encoding region of several TTV genotypes has been shown to be interrupted by
a stop codon dividing ORF2 into two parts: a smaller, more conserved ORF2a, and a larger,
more variable ORF2b (Erker et al., 1999; Tanaka et al., 2000b). Our genotype-6 isolate also
had a stop codon within ORF2, dividing it into ORF2a and ORF2b (I). Based on the
transcription map of genotype 6 (III), ORF2a would not be expressed since the splicing
removes  ORF2a and  also  39  amino acids  from the  N-terminus  of  ORF2b,  resulting  in  an
ORF2 protein that is 79 amino acids long. However, only 95% of the mRNAs were spliced
at the first common intron deleting ORF2a (III), thereby leaving the remaining 5% of
mRNAs with a potential to encode the ORF2a protein. Of note, the ORF2a sequence is
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highly conserved among all TTV genotypes (I), and could serve some important function
for the virus.
The ORF2 region is included also in the ORF2/2 and ORF2/3 encoded proteins: alternative
splicing combines it into two reading frames, resulting in proteins with identical N-termini
but  different  C-termini.  The  complete  transcription  map  of  genotype  6  is  presented  in
Fig.12.
3.2 Translation and subcellular localization of the proteins (III)
Translation of the six TTV proteins within cells was verified by immunoblotting and by
visualization of the HA or GFP-tagged proteins with fluorescence microscopy.
The ORF1-encoded protein was not detected by HA-antibodies in immunoblot, though its
mRNA  levels  comprised  over  half  of  the  total  cellular  RNA  (for  discussion,  see  4.1).
However, the ORF1 protein was detected as a GFP-tagged construct in the cytoplasm of the
living cells, thus confirming its expression. ORF1 of TTV is predicted to encode a capsid-
and replication-associated protein (Erker et al., 1999; Luo et al., 2002; Mushahwar et al.,
1999; Takahashi et al., 1998; Tanaka et al., 2001). Like a similar protein in circoviruses, the
TTV ORF1-encoded protein has an arginine-rich N-terminus (Hijikata et al., 1999b;
Mushahwar et al., 1999; Okamoto et al., 1998b; Takahashi et al., 1998; Tanaka et al., 2001)
that is supposed to be involved in DNA binding (Erker et al., 1999) and to contain putative
nuclear localization signals (Bendinelli et al., 2001). Our GFP-tagged ORF1-encoded
protein was localized in the cytoplasm (III), regardless of putative nuclear localization
signals. However, when the protein was expressed from the cDNA, instead of the full-
length clone, in 293T, HuH7 and 911 cells it localized into spot-like structures within the
nucleus (our unpublished data). Of note, the cDNA construct was not mutated at the splice
site, and thus in addition to the ORF1-encoded protein, it also was cabable to encode the
ORF1/1 protein. It is known that viral and/or cellular proteins interact with and regulate the
expression  and  localization  of  their  associated  proteins.  For  example  PCV  proteins  show
variable localization during infection: the Rep protein is consistently nuclear, while the Cap
protein is first localized in the nucleoli and then dispersed throughout the nucleoplasm and
the cytoplasm (Finsterbusch et al., 2005). It is probable that during TTV infection and
protein production, interactions of viral proteins take place, affecting their subcellular
localization, and possibly their function.
The ORF2-encoded protein translated from our full-length clone was localized in the
cytoplasm of the transfected cells. The ORF2-encoded protein of TTMV has been shown to
act as a phosphatase, proteins known to regulate mitogenesis, transcription, signal
transduction, cell-cell interactions, cellular differentiation and cytokine responses of
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lymphocytes (Peters et al., 2002). This activity is located within a motif in common with
the  ORF2  proteins  of  CAV,  TTV,  TTMV,  and  TTMDV/SAV.  The  same  motif  was  also
found in the ORF2-encoded protein of our HEL32 isolate (I), suggesting that it also may
have phosphatase activity.
In addition to the ORF1- and ORF2-encoded proteins, four more proteins were confirmed
to be produced in transfected 293 cells, from our genotype-6 clone: The ORF2/2 protein
was localized in the nucleus, as was also the ORF2/3 protein, while the ORF1/1 and
ORF1/2 proteins were distributed evenly in the cytoplasm and in the nucleus. The ORF3-
encoded protein (corresponding to ORF2/2 of this study) of genotype 1a has at the amino
acid  level  similarities  to  a  non-structural  protein  of  HCV  (Asabe  et  al.,  2001).  However,
nothing is known of the functions of the TTV proteins described.
It is possible that, in different cell types or under certain circumstances, mRNA splicing
and protein production of TTV could be altered. As shown by Leppik and coworkers it is
possible that even additional mRNAs and proteins could be produced by intragenomic
rearrangements. Furthermore, they observed cell type-specific transcription of TTV
mRNA, potentially leading to production of different mRNAs in different cell types
(Leppik et al., 2007). It should be investigated whether the six proteins that are produced by
our TTV clone, are produced also by other genotypes. For example the non-pathogenic
PCV1 and the pathogenic PCV2 differ in the numbers of mRNAs produced (12 vs. 9,
respectively) and in the splice junction selection, thus leading to transcription of both
shared and unique mRNAs (Cheung, 2003a; Cheung, 2003b). Whether similar differences
could exist between the TTV genotypes, and what their function would be, are interesting
questions for further research.
Our results, demonstrating the translation of six proteins, have revolutionized the TTV
proteomics. We have shown that instead of three to four proteins produced by overlapping
reading frames and by splicing, the coding capacity of this small virus is even further
expanded by alternative translation initiation. Apart from the localization, nothing is known
of the functions of these proteins. Thus the transcription map, the full-length clone, and the





The immunology of TTV infections is an intriguing issue. Since TTV establishes persistent
viremia in healthy immunocompetent individuals, it must have effective mechanisms for
evasion of the immune system. CAV of chickens is known to be immunosuppressive, and it
has been speculated whether TTV also could have some effects on our immunity. In order
to study the immunology of a virus, the viral proteins need to be produced for use as
antigens in immunological assays. Our Study III revealed that the HEL32 isolate is capable
of producing altogether six proteins, whereby we pursued to express them all.
4.1 Expression of TTV proteins in prokaryotes and in insect cells (I, V)
We cloned the ORFs in frame with GST, and expressed the GST-fusion proteins in E. coli.
In addition, we cloned ORF1, ORF1 Arg, ORF1-N, ORF1-C, ORF2/2, ORF2/3 and
ORF1/1 (covering all the reading frames) for expression in insect cells.
The expression of a complete ORF1 protein was not successful (I, V), which could be due
to its relatively large size, or to the arginine-rich N-terminus, or to cytotoxicity. Even the
eukaryotic expression of ORF1 in 293 cells was noticed to occur at very low levels (III),
suggesting that the ORF1 protein production is tightly regulated or that the protein is
unstable, i.e. rapidly degraded. It is also possible that, to achieve proper folding, co-
expression of other viral proteins is needed, as it is with the CAV capsid protein VP1,
which for proper folding needs the function of the scaffold protein VP2 (Noteborn et al.,
1998; Todd et al., 1990). Nevertheless, we were able to express ORF1 in two parts, as have
others (Handa et al., 2000; Ott et al., 2000), and furthermore as an arginine-rich-region-
deleted, near-complete (lacking only 62 amino acids from the N-terminus) construct (V).
The  ORF2  proteins,  both  ORF2a  and  ORF2b,  as  well  as  the  spliced  ORF2,  ORF2/2  and
ORF2/3-encoded proteins were successfully produced in bacteria (the two latter also in
insect cells) (I, V). The ORF2/2 and ORF1/2-encoded proteins are highly enriched in serine
residues at their C-termini. Asabe and coworkers have shown that ORF3 (which equals to
our ORF2/2) produced by TTV genotype 1a is expressed as two forms that differ in their
phosphorylation state (Asabe et al., 2001). Similarly, we have noted two forms of the
eukaryotically produced ORF2/2 protein in the immunoblots, which probably represent the
differentially phosphorylated forms. Whether similar phosphorylation occurs on the
ORF1/2-encoded protein is not known. In our expression studies, we noted that the
arginine-rich N-terminus affects the expression of the proteins in bacteria: the expression
level of the complete ORF1/2 was quite low, however, when the arginine-rich part was
deleted, it increased dramatically. A similar phenomenon has been noted in the expression
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of the BFDV capsid protein (Johne et al., 2004). On the other hand, the expression of
ORF1/1  was  not  very  successful,  neither  in  the  absence  of  the  arginine-rich  part  nor  in
insect cells; the reason for this is not known. It is possible that some characteristic in the
mRNA or in the protein itself makes it unstable or difficult to translate. It is also possible
that with some other expression vector and/or some other fusion part, the expression could
be more prominent, as has been shown with the PCV2 capsid protein (Liu et al., 2001).
Taken together, we were able to express all the proteins of TTV genotype 6. The expression
of  ORF1  as  a  complete  protein  was  not  successful,  but  the  entire  coding  region  became
covered with partial constructs. This is the first time that all six proteins of TTV have been
expressed in any system.
4.2 Detection of antibodies against the TTV proteins (I, V)
To study the prevalence of antibodies against the proteins expressed, we used them as
antigens in immunoblotting, and screened sera of nonsymptomatic subjects for the presence
of TTV specific antibodies.
Although ORF2a mRNA has not been detected (III), antibodies against the encoded protein
were detected in human sera (I). We analyzed by immunoblotting, using the ORF2a and
ORF2b products (fp2a and fp2b, respectively), serum samples of 89 subjects. We found
strong IgM reactivities against fp2a in 2/87 (2%) subjects, and against fp2b in 6/87 (7%).
Of these 8 subjects, 6 were TTV-DNA positive with UTR-PCR. Strong IgG reactivities
against fp2a were not detected, whereas strong IgG reactivities against fp2b were detected
in 9/87 (10%) of the subjects, who all had also TTV DNA in blood. Of the 63 TTV
antibody-negative subjects, 55 (87%) had TTV DNA in serum. Of 35 selected subjects (17
seropositive and 18 seronegative), three had TTV DNA of genotype 6: two were IgG
positive for fp2b and one was seronegative. For example of immunoblots done with human
sera, see Figure 5 in I.
We also studied 25 human sera by immunoblotting for the presence of IgG antibodies
against all the six TTV proteins (expressed in bacteria and/or in insect cells). Of the sera,
20/25 (80%) were TTV DNA positive, and 4/25 (16%) were genotype-6 DNA positive.
Altogether 11/25 (44%) had a strong IgG responses and 5/25 (20%) had no responses for
any of the proteins. However, no universal pattern in the protein-specific immune reactions
could be seen: IgG antibodies against the ORF2 protein were detected in 6/21 (28.6%),
against ORF2/2 in 1/19 (5.3%), against ORF2/3 in 5/21 (23.8%), against ORF1/1 in 1/18
(5.6%) and against ORF1/2 in 0/24 (0%) subjects. IgG antibodies against ORF1 were
detected in 2/21 (14.3%) of the subjects, all of whom showed reactivity against the C-
terminus. Ott and coworkers have also detected antibodies against the C-terminus of
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genotype-1 ORF1, yet at a higher prevalence of 98.6% (Ott et al., 2000). Handa and
coworkers have detected antibodies against the N-terminus of ORF1 of genotype 1b in 38%
of blood donors in the USA (Handa et al., 2000). In contrast to this, we found no antibodies
against  the  N-terminus  of  genotype  6  ORF1.  The  reason  could  be  an  immunological
difference between the genotypes; for example genotype 1 could be more prevalent, could
be more immunogenic, or could more readily cross-react with antibodies against other
genotypes. However, no studies on genotype-specific antibody affinities nor on antibody
cross-reactivities between TTV genotypes exist.
The relatively low IgG prevalence in general observed in our TTV studies could reflect that
genotype 6 proteins elicit genotype-specific antibodies, and/or that some of them, e.g.
intracellular non-structural viral proteins, are not regularly accessible to the immune
system. In any case, the simultaneous presence of TTV DNA and antibodies indicates that
the antibodies are not neutralizing and/or cross-protective. It remains to be investigated
whether some of these proteins, or of their epitopes, could be used as general or
genotype/genogroup-specific markers for TTV infections, i.e. as diagnostic tools.
4.3 Follow-up studies (I, V)
We retrospectively analyzed select subjects for the presence of TTV DNA and antibodies.
In Study I, we had follow-up samples from four subjects, spanning 1.5 to 15 years of time
(Table 3). Two subjects had stable TTV DNA and antibody status: strong IgM reactivity for
fp2b and TTV DNA positivity. Two subjects had an altering phenotype: subject #1 showed
strong IgM against fp2b for three years, and also strong IgG reactivity for fp2a throughout
the 12-year follow-up, at the end of which she became positive for TTMV DNA; #97 was
followed up for 1.5 years and he had fluctuating borderline reactivities for fp2b IgM and
fp2b IgG, converting to positivity for TTMV DNA at the end of the follow-up period.
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Table 3. Prevalence  of  TTV  DNA  and  antibodies  against  two  ORF2  proteins  in  four
subjects followed for 1.5 to 15 years.
TTV DNA -    - - -   - -  -  +
IgM/fp2a -    - - -   - -    -
IgM/fp2b +    + + +/- +/- +/-  -   -
IgG/fp2a +    + + +   + +  +  +
#1
IgG/fp2b - +/- -  - +/- -   -   -
TTV DNA +      + +   + +        +
IgM/fp2a -     - -  - -       -
IgM/fp2b +      + +   + +        +
IgG/fp2a -      -            -
#26
IgG/fp2b -      -            -
TTV DNA + +     + +        +
IgM/fp2a - -     - -        -
IgM/fp2b + +     + +        +
IgG/fp2a -                -
#55
IgG/fp2b -                -
TTV DNA -  - +
IgM/fp2a -   -
IgM/fp2b +/- +/- -
IgG/fp2a -   -
#97
IgG/fp2b +/-  -  -
Time in years 0 0.5 1 1.5 2 3 4 5 6 7 8 9 1 0 1 1 1 2 1 3 1 4 1 5
The continued presence of TTV DNA in sera of healthy subjects is a well-documented
phenomenon. However, others have shown, with different serological methods, the
occurrence of short-lived IgM antibodies (Tsuda et al., 2001), as opposed to our long-
lasting IgM. The reason for the longevity of the IgM detected in our study is not known, but
one possibility could be impaired T-helper cell activity caused by T-cell cross-tolerance
against multiple TTV genotypes.
In Study V, we had follow-up samples from four additional subjects. In two subjects no
changes in virus DNA or in antibodies was seen: subject #2 was TTV DNA negative and
seropositive for the ORF1, ORF1/1 and ORF1/2-encoded proteins; #80 was TTV-DNA
negative and borderline seropositive for ORF1. Of the remaining two subjects, #86 had
TTV DNA in serum through the follow-up of 13 years. She became genotype-6 DNA
positive and sero-converted to IgG seropositivity for the ORF2-encoded protein in a sample
taken two years later, and remained IgG seropositive thereafter. Interestingly, in the sample
taken three years later, the genotype-6 DNA had disappeared. Subject #32 from whom the
HEL32 clone originated, remained genotype-6 DNA positive throughout the follow-up, for
at least 8 years. She was also continuously strongly IgG seropositive for the ORF1-encoded
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protein. Both the sequences and the relative titers of genotype-6 DNA remained unaltered
in both of the genotype-6 DNA positive subjects.
In conclusion, all the proteins were shown to be immunogenic. However, no correlation in
antibody patterns between individuals was seen. Our follow-up results showed that 1) IgM
against ORF2b can co-exist with TTV DNA for years, 2) superinfections with anelloviruses
can  occur  regardless  of  pre-existing  antibodies,  3)  ORF1  antibodies  and  the  DNA  of  the
same genotype can co-exist for several years, and 4) the appearance of IgG against the
ORF2-encoded protein occurred in conjunction with the disappearance of the DNA of the
same genotype (for further discussion, see 4.4). In addition, the genotype-6 sequence
remained unchanged throughout the follow-up, indicating that some mechanisms other than
mutations could be used by TTV for immune evasion. However, it has to be kept in mind
that immunoblotting tends to favour linear over conformational epitopes, and during the
course of infection this proportion, i.e. the conformational dependence of antibodies, might
change, as has been shown with human parvovirus B19 (Kaikkonen et al., 1999; Söderlund
et al., 1995). Therefore the antibody responses detected in immunoblots could represent
only a one time-window during the course of infection. Other techniques, such as ELISA,
need to be developed to get the complete picture of antibody responses during TTV
infections.
4.4 Immunological scenarios for TTV infections
The response to and the outcome of a virus infection depends on viral parameters such as
cytopathogenicity, kinetics, cell and tissue tropism, host reservoirs, and susceptibility to
other resistance mechanisms (such as interferons); as well as on the immune system
including the specificity, kinetics and duration of humoral and cell-mediated immunity, in
conjunction with the actions of the complement system, interleukins and phagocytes. For a
virus it is optimal to achieve a clinically inapparent infection, or a balance between the host
immune system and a tolerable disease state (Hilleman, 2004; Zinkernagel, 1996).
Another small DNA virus, human papillomavirus, is known to escape and control immune
reactions in several ways: the innate immunity has difficulties in recognizing the virus
because, for example, it is not cytolytic, it has no envelope, and it does not express proteins
on the plasma membrane of the infected cells. Due to the difficulties in the initiation of an
innate immune response, the adaptive immune response may remain defective also.
However, a bacterial superinfection may activate the immune system to recognize also the
papillomaviruses and the cytotoxic T cells to clear the viral infection (Skern, 2006). In
general, the persistent viruses with low cytopathogenicity can evade or delay neutralizing B
cell responses via 1) low numbers of activated B-cells, 2) alteration of the B-cell repertoire,
3) alteration of T-helper cell function, or 4) immunopathological changes in lymphoid
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tissues (Hangartner et al., 2006). Perhaps TTV could use some or several of these
mechanisms for evasion of the immune system.
Based on our and others’ serological data it is evident that some form of immune responses
against TTV occur in humans (Tsuda et al., 1999; Tsuda et al., 2001; I; V), and that TTV
may occur in sera as immunecomplexes with IgG (Itoh et al., 2000), especially during
persistent infection (Nishizawa et al., 1999). Interestingly, a superinfection with a new TTV
strain has been shown to decrease the amount of immunecomplexes, followed by clearance
of the new infection. The authors proposed that secondary, as opposed to persistent
infections, might be more effectively cleared by preformed antibodies (Maggi et al., 2006).
It  has  also  been  shown  that  over  90%  of  TTVs  are  cleared  from  the  circulation  and
replenished by progeny viruses, thus indicating chronic active infection (Maggi et al.,
2001c). In any case, frequent superinfections in healthy individuals with several genotypes
suggest that (some) immune responses are neither neutralizing nor cross-protective.
The disappearance of genotype-6 DNA from the circulation after appearance of antibodies
against the ORF2-encoded protein, which most probably is intracellular, was quite
intriguing. It is tempting to speculate that the antibodies could clear the virus by helping in
the destruction of the infected cells; whereas the humoral response against the ORF1-
encoded putative capsid protein could be non-neutralizing and therefore unable to block,
and eradicate, the viral infection. In addition, the antibodies could opsonise the virus for
cellular intake. The low expression of the putative capsid protein in eukaryotic cells could
furthermore represent one mechanism of immune response control; the less capsid protein
is produced, the weaker is the antigen presentation. In addition, fragmented ORF1s may
yield defective virus particles (Jelcic et al., 2004; Luo et al., 2002), which could exhaust the
immune system. Although our results point to stability of the genotype-6 DNA sequence
for years, it is possible that TTV evades the immune system also by mutating its critical
epitopes on the capsid surface. Furthermore, transplacental transmission of TTV,
potentially affecting self-nonself-discrimination, could also help the virus to avoid the
immune response and to establish persistence. It is also possible that the brain and liver,
expressing the HLA-I molecules in low levels, could avoid cell destruction by cytotoxic T
cells and thereby could act as reservoirs for persistent TTV viremia (Griffiths, 1999).
As the closely related CAV is known to be immunosuppressive in chickens, TTV also has
been investigated from this point of view. Maggi and coworkers have shown that the
numbers of T cells decreased and B cells increased with increasing TTV loads, suggesting
that TTV replication could cause immune imbalance (Maggi et al., 2003c). Zheng and
coworkers have shown that TTV ORF2 protein blocks the NF- B pathway, thus potentially
suppressing immune responses and aiding in the establishement of persistent infection
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(Zheng et al., 2007). In addition, CAV VP2 has been shown to cause down regulation of
MHC-I class molecules on the plasma membrane of the infected cells, thereby reducing the
presentation of viral peptides to the immune system. This function has been mapped to the
dual specificity protein phophatase site of CAV VP2 protein (Peters et al., 2006). The same
phosphatase activity has also been demonstrated in the TTMV ORF2 protein, a sequence
present  also  in  the  ORF2 of  TTV (Peters  et  al.,  2002).  Furthermore,  whether  infection  of
PBMCs by TTV exerts any effects on the virus-specific immunity remains to be studied.
TTV  is  a  very  small  virus  and  does  not  possess  the  genetic  capacity,  as  do  for  example
herpesviruses, to encode a number of proteins for immune evasion. Nevertheless, TTV
seems to have adapted very well to its host(s). This kind of co-existence and co-evolution is
a very effective way for a virus to achieve its main goal: to replicate and spread. In order
for us to achieve a full picture of TTV and its interplay with our immunity, we must
produce and analyze proteins of also other genotypes for cross-reactivity, for
conformational and linear epitopes, and for antibody isotypes and affinity/avidity. In
addition, the role of T-cell function in TTV infections needs to be elucidated.
5 TORQUE TENO VIRUS: A PATHOGEN, A CONSTITUENT OF THE
NORMAL FLORA, OR BOTH?
It is obvious that TTV infections are extremely prevalent even in healthy individuals, and
no definitive causal association with TTV infection has been found for any of the diseases
investigated. However, it should be noted that due to the lack of tools for immunological
studies TTV research has focused mainly on detection of TTV DNA; and due to sub-
optimal PCR methods, the detection and identification of many of the anelloviruses has not
been possible.
Viruses can cause diseases by a number of different mechanisms: directly by cell
destruction, or by inducing genetic or cellular alterations, and indirectly by interfering with
the immune system. It has been said that viruses are guilty until proven innocent, and TTV,
let alone the other human anelloviruses, certainly have not yet convinced the jury. It is
possible that some genotypes of TTV are pathogenic, as is the case with PCV and HPV. In
addition, many long-term chronic microbial infections are known to predispose to
chronically evolving diseases, a phenomenon which shall be extremely difficult to elucidate
with such a ubiquitous virus as TTV.
However,  it  is  also  possible  that  TTV is  a  genuinely  harmless  bystander  with  no  adverse
effects whatsoever on human health (Griffiths, 1999; Simmonds et al., 1999). Pathogens of
the normal flora (typical for bacteriology) do not induce disease in every individual
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infected. On the other hand, as with opportunistic pathogens the disease appears only under
exceptional circumstances. In some virus infections the viral load is a critical determinant
for development of the disease. It has been suggested that TTV could be a commensal in
normal conditions not capable of exceeding the threshold of a disease-causing load
(Griffiths, 1999). Commensal bacteria live on our surfaces, whereas viruses invade our
body and our cells. Therefore the conclusion that anelloviruses are endosymbionts is
justified (Mushahwar et al., 2001). However, for genuine symbiosis the virus should benefit
the host – an intriguing aspect hitherto unexplored with TTV.
It is very probable that anelloviruses have co-evolved with us and other animals for
millions  of  years.  Evidence  to  support  this  comes  from  the  study  showing  that  TTV  and
TTMV sequences identified in non-human primates form their own sequence clusters, with
increasing divergence from human isolates, suggesting co-evolution and co-specification
within their respective species (Thom et al., 2003). Similar phylogenetic clustering and co-
evolution has been shown with the species-specific evolution of e.g. the hantaviruses
(Plyusnin et al., 1996). This long-term virus-host co-evolution could help understand the
existence of the numerous TTV genotypes and the possible lack of strong immune
responses.
In  all,  it  is  obvious  that  (nearly)  all  humans  (in  addition  to  many  other  species)  carry
anelloviruses. These viruses are actively replicating within us, and as it seems have
achieved the euphoria of virus life: apparently unlimited replication and spread all over the
world.
6 FUTURE ASPECTS IN TORQUE TENO VIRUS RESEARCH
To understand the TTV life cycle, the following key issues should be addressed: 1)
methods should be developed to detect, to quantify, and to separate all the existing
anelloviruses; 2) new genotypes and/or TTV-like viruses, as yet unknown, should be
searched for; 3) proteins from various genogroups need to be expressed; 4) antibodies
against the proteins should be produced; and 5) efficient cell culture systems for virus
production should be set up. With these tools, some of which have been developed in this
thesis work, the cell biology, immunology, pathology, and epidemiology of this new virus
family can be uncovered.
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Supplement 1. The GenBank submission #AY666122 containing all the information on the
isolate HEL32 of genotype 6. (Reproduced from http://www.ncbi.nlm.nih.gov)
LOCUS       AY666122    3748 bp    DNA     circular VRL 13-SEP-2007
DEFINITION  TT virus genotype 6 strain HEL32, complete genome.
ACCESSION   AY666122 AY034068
VERSION     AY666122.2  GI:157165913
SOURCE      TT virus genotype 6
ORGANISM    TT virus genotype 6
            Viruses; ssDNA viruses; Anellovirus.
REFERENCE   1  (bases 1 to 3748)
AUTHORS     Kakkola,L., Hedman,K., Vanrobaeys,H., Hedman,L. and
            Soderlund-Venermo,M.
TITLE       Cloning and sequencing of TT virus genotype 6 and expression
            of antigenic open reading frame 2 proteins
JOURNAL     J. Gen. Virol. 83 (Pt 5), 979-990 (2002)
PUBMED      11961251
REFERENCE   2  (bases 1 to 3748)
AUTHORS     Qiu,J., Kakkola,L., Cheng,F., Ye,C., Soderlund-Venermo,M.,
            Hedman,K. and Pintel,D.J.
TITLE       Human circovirus TT virus genotype 6 expresses six proteins
            following transfection of a full-length clone
JOURNAL     J. Virol. 79 (10), 6505-6510 (2005)
PUBMED      15858033
REFERENCE   3  (bases 1 to 3748)
AUTHORS     Kakkola,L., Tommiska,J., Boele,L.C., Miettinen,S., Blom,T.,
            Kekarainen,T., Qiu,J., Pintel,D., Hoeben,R.C., Hedman,K. and
            Soderlund-Venermo,M.
TITLE       Construction and biological activity of a full-length
            Molecular clone of human Torque teno virus (TTV) genotype 6
JOURNAL     FEBS J. 274 (18), 4719-4730 (2007)
PUBMED      17714512
REFERENCE   4  (bases 1 to 3748)
AUTHORS     Kakkola,L., Hedman,K., Vanrobaeys,H., Hedman,L. and
            Soderlund-Venermo,M.
TITLE       Direct Submission
JOURNAL     Submitted (08-MAY-2001) Department of Virology, Haartman
            Institute, University of Helsinki, Haartmaninkatu 3, Helsinki
            P.O.B. 21, 00014, Finland
REFERENCE   5  (bases 1 to 3748)
AUTHORS     Kakkola,L., Tommiska,J., Hedman,K. and Soderlund-Venermo,M.
TITLE       Direct Submission
JOURNAL     Submitted (23-JUN-2004) Department of Virology, Haartman
            Institute, University of Helsinki, P.O.B. 21 (Haartmaninkatu
            3), Helsinki 00014, Finland
REFERENCE   6  (bases 1 to 3748)
AUTHORS     Kakkola,L., Tommiska,J., Hedman,K. and Soderlund-Venermo,M.
TITLE       Direct Submission
JOURNAL     Submitted (13-SEP-2007) Department of Virology, Haartman
            Institute, University of Helsinki, P.O.B. 21 (Haartmaninkatu
            3), Helsinki
            00014, Finland
REMARK      Sequence update by submitter
COMMENT     On Sep 13, 2007 this sequence version replaced gi:51477325.
FEATURES    Location/Qualifiers
     source          1..3748
                     /organism="TT virus genotype 6"
                     /mol_type="genomic DNA"
                     /strain="HEL32"
                     /db_xref="taxon:290650"
                     /country="Finland"
                     /note="genotype: 6"
     misc_difference 1..5
                     /note="compared to previous sequence in AY034068.1"
                     /replace="tttgcta"
     misc_difference 69
                     /note="compared to previous sequence in AY034068.1"
                     /replace="g"
     TATA_signal     82..87
     CDS             join(354..703,2505..2982)
                     /codon_start=1
                     /product="ORF2/3"
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                     /protein_id="ABV25031.1"
                     /db_xref="GI:157165915"





     CDS             join(354..703,2315..2810)
                     /codon_start=1
                     /product="ORF2/2"
                     /protein_id="ABV25033.1"







     CDS             354..707
                     /codon_start=1
                     /product="ORF2"
                     /protein_id="ABV25034.1"
                     /db_xref="GI:157165918"
                     /translation="MWQPPTQNGTQLERHWFESVWRSHAAFCSCGDCIGHLQHLATNL
GRPPAPQPPRDQHPPHIRGLPALPAPPSNRNSWPGTGGDAAGGEAGGSRGAGDGGDGE
LADEDLLDAIALAAE"
     CDS             join(581..703,2505..2810)
                     /codon_start=1
                     /product="ORF1/2"
                     /protein_id="ABV25030.1"
                     /db_xref="GI:157165914"
                     /translation="MAWYWWRRRRRRGWWKPRRRRWRRRRARRRGPARRHRARRRSTD
PNAPRETPRSKKKRPKKTQIQQSNSEDSSPGSTPVKKQKTKRRRYRRARYKNNFSSSS
SSSDSSESSSSPLPKKSSKSGGGTASTPYYLPMHKQGLYV"
     CDS             581..2791
                     /codon_start=1
                     /product="ORF1"
                     /protein_id="ABV25035.1"
                     /db_xref="GI:157165919"













     CDS             join(581..703,2315..2791)
                     /codon_start=1
                     /product="ORF1/1"
                     /protein_id="ABV25032.1"
                     /db_xref="GI:157165916"




     polyA_signal    2978..2983
     misc_difference 3362
                     /note="compared to previous sequence in AY034068.1"
                     /replace=""
     misc_difference 3376
                     /note="compared to previous sequence in AY034068.1"
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                     /replace="g"
1    aagatcgtca ctaaccacgt gactctccac agcgaaccac tggtgtacgt gattcacttc
61   ctgggcgtaa cttatgtact catataagta actgcacttc cgaatggctg agttttccac
121  gcccgtccgc agcggcagca cctcgaaggg tgatccccgc gtcccgaggg cgggtgccga
181  aggtgagttt acacaccgca gtcaaggggc aattcgggct cgggactggc cgggctatgg
241  gcaaggctct tagggtattc actcttaaaa tgcacttttc tagaatctct cgctcgaaaa
301  ggaaagtgtt tctgccggca ctgccagctc caccgccgcc taggcaactt ctaatgtggc
361  agccacctac ccagaatgga acccaactcg aacggcactg gttcgagtcc gtttggcgtt
421  cgcatgctgc cttttgtagc tgtggcgact gtattggcca tcttcagcat ctggctacta
481  acctgggtcg accacctgct ccacaaccgc cgcgagacca acacccaccg cacataagag
541  ggctcccggc actcccggca cctcccagta acagaaactc atggcctggt actggtggag
601  acgccgccgg aggagaggct ggtggaagcc gaggcgcagg agatggagga gacggagagc
661  tcgcagacga ggacctgcta gacgccatcg cgctcgccgc agagtaagga ggcgaagggg
721  gaggtggagg agacgataca gacgctggcg cagacgcggg gggcgacgca gacacagaaa
781  aaaactaata attaaacagt ggcaacctaa ctttattaga cactgctaca taataggata
841  catgccactg ataatatgtg gagagaacac tttctcccac aactatgcca cccactcgga
901  cgatatgctc tctacagggc cctacggagg gggcatgact accacaaaat tcaccctaag
961  aatactcttt gacgagtacc aaagacactt aaatttctgg accgttagca accaagacct
1021 agacctagcc aggtacctgg gaacaaaaat catcttcttt agacacccca cggtagactt
1081 tgtggtacaa atacacacac agcctccctt ccaagacaca gagataacag cacccagcat
1141 acacccagga atgctcatac tctctaagaa acacatacta atacccagcc taaaaaccag
1201 gccctctaaa aaacactatg taaaagttag agtaggggcc ccaagactct ttcaggacaa
1261 gtggtacccc cagagcgagc tctgtgacgt cacattactc gttatctatg caaccgcatg
1321 tgacttgcaa tatccgttcg gctcaccaca aactgacaac gtatgtgtca acttccagat
1381 attggggcaa ccctattacc aacacctcaa gacggcctta ggcttaactg aaaaaaccac
1441 atacgaaaac cactataaaa ataacttata taagaaaatt aaattttata acactacaga
1501 aacaatagca caactaaaac ctctagtaga tgctactacc aatcaaacct ggtcacatta
1561 cgtaaaccct aataaactta caacaacacc tacatcagaa ataacccata ataacacatg
1621 gtacagaggc aatgcataca atgacaaaat tacagaccta cctgaaatag taaaaaaaag
1681 ctattataaa gccacagaac ttgctatacc agaagcagta aaacccacca cagacttatt
1741 tgagtaccac gcaggcatat acagctccat attcctgtcc ccaggaagag catactttga
1801 gacccctgga gcataccaag acataattta caatcccttt acagacaaag gaataggaaa
1861 catagtgtgg atagactggc tcagtaaatc agacgcagta tactcagaaa agcaaagcaa
1921 atgtggtata tttgacctac ctctatgggc agccttcttt ggatatgcag agttctgctc
1981 caaaagcaca ggagacacag ccatagcata caacagcaga gtatgtgtta gatgcccata
2041 cacagagcca cagctgttaa accacaacaa cccctcacag ggatatgtgt tttactctta
2101 caactttggc aaaggcaaga tgcccggagg cagttcccag gtacctataa gaatgaggtg
2161 gaaatggtac gtgtgcatgt tccaccagct agaggtcatg gaagctatat gccaaagcgg
2221 accgtttgca tatcacagcg acgaaaaaaa agcagtacta ggcataaaat ataagttcga
2281 ctggaaatgg ggaggaaatc ctatctccca acagatcgtc cgacacccct gcaacggaca
2341 gacctcctca ggcaatagag tgcctcgctc agtacaagca gttgacccga aatacgtctc
2401 actccaactc gtgtggcact cgtgggactt cagaagaggc ctctttggcc aggcaggtat
2461 taagagaatg caacaagaat cagatgctct tacactttct ccagtccaca gacccaaacg
2521 ccccaagaga gacacccagg tcaaagaaaa aacgcccgaa aaagactcag attcagcagt
2581 ccaactcaga agactccagc cctggatcca ctccagtcaa gaaacaaaag acgaagagga
2641 ggagataccg gagggcccgg tacaagaaca acttctccag cagctccagc agcagcgact
2701 cctcagagtc cagctcgagt ccattgccca agaagtcctc aaaatcagga gggggcacag
2761 cctccacccc ctactatctt cccatgcata aacaaggtct ttatgtttaa ccctccaggt
2821 ccaaaacgca tcactgggta cgaggcctgg agggatgaat atgaaacatg caaggcctgg
2881 aacaggcccc ctagatcctt ttacacagat attcccacat acacctggat gcccaaagcc
2941 caagaccaat ttcgtgtaag cttcaaactt ggctttcatt aaaatttcaa ggccgtgcaa
3001 cattcacttg tcggtgtcta cctctaaagg tcactaagca ctccgagcgc aagcgaggag
3061 tgcgaccctc cccccctggg gcaactccct cgaagtccgg cgctacgcgc ttcgcgctgc
3121 gccggacatc tcggaccccc cctccacccg aaacgcttgc gcgtttcgga ccttcggcgt
3181 cgggggggtc gggggcttta ctaaacagac tccgagatgc cattggacac tgagggggca
3241 tacagcaacg aaagtgagtg gggccagact tcgccataag gcctttatct tcttgccatt
3301 tgtcagtata gggggtcgcc ataggcttcg gcctccattt taggccttcc ggactacaaa
3361 aatggccgtt ccagtaacgt cacggccgcc attttaagta ggtgccgtcc agcactgctg
3421 ttccgggtta aagggcatcc tcggcggaac ctatacaaaa tggccgccaa tttcttccgg
3481 gtcaaaggtc acgcctacgt catcgatgac gtggggaggc gtactatgaa acgcggaagt
3541 aggccccgct acgtcatcat cacgtgggtg ctgcgtcacg gccgccattt tgttttacaa
3601 aatggccgac ttccttcctg ttttttaaaa attaaccgtt agcggcggcg cgcgcgcttc
3661 gcgcgcgcgc cggggggctc cgcccccccc ccgcgcatgc gcggggcccc ccccccgcgg




Torque teno virus (TTV) is highly prevalent among the general population
throughout the world. Virtually nothing is known of the cell biology or the proteins of
TTV. In this work we have determined the prevalence of TTV in Finland, studied the cell
biology, and expressed all the six proteins of TTV for immunological studies.
Torque teno viruses were found to be highly prevalent also in Finland; 85% of
healthy adults had ongoing viremia. Genotype-6 DNA was detected in 4% of sera, and also
in a number of different tissues, with no tissue-type or symptom specificity.
A full-length clone constructed of TTV genotype 6 was shown to transcribe
mRNAs  in  all  the  cell  lines  tested.  DNA  replication  was  determined  to  occur  in  several
human cell lines, with the highest expression levels observed in human kidney-derived
293T cells. Viral DNA replication was shown to use the cellular replication machinery,
representing the first replication-related cell biological fact of the life cycle of this newly
found human virus.
The transcription map of TTV genotype 6 was determined: this small virus was
shown to produce altogether six proteins. To achieve this, the virus uses alternative splicing
and alternative translation initiation. In addition, the sub-cellular localizations of the
proteins were determined in cultured cells, leading to further need for investigations of
potential protein interactions.
The six proteins were expressed in bacteria and in insect cells, and their antigenicity
was studied. IgG antibodies against the proteins were detected in 44% of nonsymptomatic
adults. Two genotype-6 DNA positive subjects were followed: one had persisting
genotype-6 viremia with a concurrent IgG response against the putative capsid protein, and
the other had a transient genotype-6 viremia with appearance of IgG against the ORF2
protein, correlating with the disappearance of genotype 6 from the circulation. The genomic
DNA of genotype 6 remained constant throughout a follow-up of eight years,
simultaneously with a strong IgG response against the putative capsid protein, indicating
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